MDS
MCID: MYL009
MIFTS: 73

Myelodysplastic Syndrome (MDS) malady

Categories: Genetic diseases, Rare diseases, Immune diseases, Blood diseases

Aliases & Classifications for Myelodysplastic Syndrome

About this section

Aliases & Descriptions for Myelodysplastic Syndrome:

Name: Myelodysplastic Syndrome 52 11 70 12 13 35 68
Myelodysplastic Syndromes 35 48 27 50 38 39
 
Myelodysplastic Syndrome, Somatic 52 24 12
Mds 48 24 70

Characteristics:

HPO:

64
myelodysplastic syndrome:
Inheritance: somatic mutation

Classifications:



External Ids:

OMIM52 614286
Disease Ontology11 DOID:0050908
MeSH39 D009190
MedGen37 C3463824
ICD1030 D46

Summaries for Myelodysplastic Syndrome

About this section
MedlinePlus:38 Your bone marrow is the spongy tissue inside some of your bones, such as your hip and thigh bones. it contains immature cells, called stem cells. the stem cells can develop into the red blood cells that carry oxygen through your body, the white blood cells that fight infections, and the platelets that help with blood clotting. if you have a myelodysplastic syndrome, the stem cells do not mature into healthy blood cells. many of them die in the bone marrow. this means that you do not have enough healthy cells, which can lead to infection, anemia, or easy bleeding. myelodysplastic syndromes often do not cause early symptoms and are sometimes found during a routine blood test. if you have symptoms, they may include shortness of breath weakness or feeling tired skin that is paler than usual easy bruising or bleeding pinpoint spots under the skin caused by bleeding fever or frequent infections myelodysplastic syndromes are rare. people at higher risk are over 60, have had chemotherapy or radiation therapy, or have been exposed to certain chemicals. treatment options include transfusions, drug therapy, chemotherapy, and blood or bone marrow stem cell transplants. nih: national cancer institute

MalaCards based summary: Myelodysplastic Syndrome, also known as myelodysplastic syndromes, is related to hemophagocytic lymphohistiocytosis and acute lymphocytic leukemia, and has symptoms including myelodysplasia An important gene associated with Myelodysplastic Syndrome is GATA2 (GATA Binding Protein 2), and among its related pathways are HIF-1-alpha transcription factor network and Embryonic and Induced Pluripotent Stem Cell Differentiation Pathways and Lineage-specific Markers. Affiliated tissues include myeloid, bone and bone marrow, and related mouse phenotypes are Decreased influenza A H1N1 (A/Hamburg/04/2009) virus numbers and Increased shRNA abundance (Z-score > 2).

Disease Ontology:11 A bone marrow cancer that is characterized by under production of white blood cells, red blood cells and platelets.

NIH Rare Diseases:48 Myelodysplastic syndromes (mds) are a rare group of blood disorders characterized by abnormal development of blood cells within the bone marrow. individuals with mds have abnormally low blood cell levels (low blood counts). signs and symptoms associated with mds include dizziness, fatigue, weakness, shortness of breath, bruising and bleeding, frequent infections, and headaches. in some cases, mds may progress to bone marrow failure or an acute leukemia. the exact cause of mds is unknown. it sometimes runs in families, but no disease-causing gene has been identified. treatment depends on the affected individual's age, general health, and type of mds and may include red cell and/or platelet transfusions and antibiotics. last updated: 3/23/2012

OMIM:52 Myelodysplastic syndrome (MDS) is a heterogeneous group of clonal hematologic stem cell disorders characterized by... (614286) more...

UniProtKB/Swiss-Prot:70 Myelodysplastic syndrome: A heterogeneous group of closely related clonal hematopoietic disorders. All are characterized by a hypercellular or hypocellular bone marrow with impaired morphology and maturation, dysplasia of the myeloid, megakaryocytic and/or erythroid lineages, and peripheral blood cytopenias resulting from ineffective blood cell production. Included diseases are: refractory anemia (RA), refractory anemia with ringed sideroblasts (RARS), refractory anemia with excess blasts (RAEB), refractory cytopenia with multilineage dysplasia and ringed sideroblasts (RCMD-RS); chronic myelomonocytic leukemia (CMML) is a myelodysplastic/myeloproliferative disease. MDS is considered a premalignant condition in a subgroup of patients that often progresses to acute myeloid leukemia (AML).

Wikipedia:71 Myelodysplastic syndromes (MDS) are a group of cancers in which immature blood cells in the bone marrow... more...

Related Diseases for Myelodysplastic Syndrome

About this section

Diseases related to Myelodysplastic Syndrome via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 307)
idRelated DiseaseScoreTop Affiliating Genes
1hemophagocytic lymphohistiocytosis29.9CSF2, FLT3, GATA2, IL3, NPM1, NUP98
2acute lymphocytic leukemia29.8FLT3, IL3, RUNX1, WT1
3leukemia, acute myeloid28.8ACSL6, ASXL1, CSF2, EPO, FLT3, GATA2
4unclassified myelodysplastic syndrome12.0
5therapy related acute myeloid leukemia and myelodysplastic syndrome11.9
6macrocytic anemia, refractory, due to 5q deletion, somatic11.8
7acute myeloid leukemia and myelodysplastic syndromes related to radiation11.8
8acute myeloid leukemia and myelodysplastic syndromes related to alkylating agent11.8
9acute myeloid leukemia and myelodysplastic syndromes related to topoisomerase type 2 inhibitor11.8
10myelodysplastic syndrome, susceptibility, gata2-related11.7
11muscular dystrophy11.6
12miller-dieker lissencephaly syndrome11.5
13walker-warburg syndrome11.4
14myelodysplastic myeloproliferative cancer11.3
15refractory anemia with excess blasts11.3
16alpha-thalassemia myelodysplasia syndrome, somatic11.2
17myeloproliferative neoplasm11.1
1811.1
19sideroblastic anemia11.1
20dyskeratosis congenita11.1
21littoral cell angioma of the spleen11.1
22epidermolysis bullosa simplex with muscular dystrophy11.0
23leukemia, acute myelomonocytic, somatic, somatic11.0
24pulmonary fibrosis and/or bone marrow failure, telomere-related, 110.9
25neutropenia, severe congenital 1, autosomal dominant10.9
26menkes disease10.8
27epidermolysa bullosa simplex with muscular dystrophy10.8
28leukemia10.8
29refractory anemia10.8
30neutropenia, severe congenital 3, autosomal recessive10.7
31pelger-huet anomaly10.7
32pulmonary fibrosis and/or bone marrow failure, telomere-related, 410.7
33sea-blue histiocyte disease10.7
34pulmonary fibrosis and/or bone marrow failure, telomere-related, 310.7
35familial mosaic monosomy 7 syndrome10.7
36myeloid leukemia10.6
37regional odontodysplasia10.4ASXL1, GATA2, SETBP1, TET2
38acute respiratory distress syndrome10.4FLT3, GATA2, NPM1
39glycogen storage disease type 010.4FLT3, NPM1, WT1
40abdominal obesity-metabolic syndrome10.4ASXL1, RUNX1, SETBP1
41agammaglobulinemia 8, autosomal dominant10.4FLT3, GATA2, NPM1
42colorectal adenoma10.4ASXL1, FLT3, RUNX1, SETBP1, TET2
43von hippel anomaly10.4ASXL1, EPO, IL3, RUNX1, TET2
44acute zonal occult outer retinopathy10.4FLT3, NPM1
45malignant testicular leydig cell tumor10.4FLT3, NPM1, RUNX1
46nephrolithiasis10.4CSF2, NRAS, SETBP1, TET2
47familial hyperaldosteronism10.4FLT3, NRAS, RUNX1, WT1
48erythrocytosis, somatic10.4EPO, FLT3, IL3, TET2
49basilar artery insufficiency10.4ASXL1, EPO, IL3, TET2
50dic in newborn10.4CSF2, EPO, IL3

Graphical network of the top 20 diseases related to Myelodysplastic Syndrome:



Diseases related to myelodysplastic syndrome

Symptoms & Phenotypes for Myelodysplastic Syndrome

About this section


Clinical features from OMIM:

614286

Human phenotypes related to Myelodysplastic Syndrome:

 64
id Description HPO Frequency HPO Source Accession
1 myelodysplasia64 HP:0002863

GenomeRNAi Phenotypes related to Myelodysplastic Syndrome according to GeneCards Suite gene sharing:

26
idDescriptionGenomeRNAi Source AccessionScoreTop Affiliating Genes
1GR00195-A-311.0NUP98, RUNX1, SF3B1
2GR00366-A-19210.2ACSL6, FLT3, PRDM16, SETBP1, WT1

MGI Mouse Phenotypes related to Myelodysplastic Syndrome according to GeneCards Suite gene sharing:

41 (show all 12)
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:000200610.5ASXL1, CSF2, FLT3, IRF1, NPM1, NRAS
2MP:000538010.5CSF2, EPO, GATA2, NPM1, NRAS, NUP98
3MP:000287310.3EPO, GATA2, IRF1, NRAS, PRDM16, RUNX1
4MP:000537610.2ASXL1, CSF2, EPO, FLT3, GATA2, IRF1
5MP:000538410.1ASXL1, CSF2, EPO, FLT3, GATA2, IRF1
6MP:000537810.1ASXL1, CSF2, FLT3, GATA2, NPM1, NRAS
7MP:000537910.1ASXL1, CSF2, FLT3, GATA2, IRF1, NRAS
8MP:000537010.1ASXL1, EPO, GATA2, NPM1, NRAS, PRDM16
9MP:000538510.1CSF2, EPO, GATA2, IRF1, NPM1, NRAS
10MP:000538710.0ASXL1, CSF2, EPO, FLT3, IRF1, NPM1
11MP:001076810.0ASXL1, CSF2, EPO, FLT3, GATA2, IRF1
12MP:00053979.9ASXL1, CSF2, EPO, FLT3, GATA2, IRF1

Drugs & Therapeutics for Myelodysplastic Syndrome

About this section

FDA approved drugs:

id Drug Name Active Ingredient(s)16 Company Approval Date
1
Busulfex16 44 BUSULFAN Orphan Medical February 1999
FDA Label: Busulfex
Disease/s that Drug Treats:leukemia
Indications and Usage:16 BUSULFEX is an alkylating drug indicated for: Use in combination with cyclophosphamide as a conditioning regimenprior to allogeneic hematopoietic progenitor cell transplantation forchronic myelogenous leukemia (CML) (1)
DrugBank Targets:14 DNA
Mechanism of Action:16 
Target: DNA
Action: alkylyzer
FDA: Busulfan is a bifunctional alkylating agent in which two labile methanesulfonate groups are attached to opposite ends of afour-carbon alkyl chain. In aqueous media, busulfan hydrolyzes to release the methanesulfonate groups. This producesreactive carbonium ions that can alkylate DNA. DNA damage is thought to be responsible for much of the cytotoxicity ofbusulfan.
2
Lynparza16 44 OLAPARIB AstraZeneca December 2014
FDA Label: Lynparza
Disease/s that Drug Treats:previously treated BRCA mutated advanced ovarian cancer
Indications and Usage:16 Lynparza is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated asmonotherapy in patients with deleterious or suspected deleterious germlineBRCA mutated (as detected by an FDA-approved test) advanced ovariancancer who have been treated with three or more prior lines of chemotherapy.(1.1)The indication is approved under accelerated approval based on objectiveresponse rate and duration of response. Continued approval for this indicationmay be contingent upon verification and description of clinical benefit inconfirmatory trials. (1 1, 14)
DrugBank Targets:14 1. Poly [ADP-ribose] polymerase 1;2. Poly [ADP-ribose] polymerase 2;3. Poly [ADP-ribose] polymerase 3
Mechanism of Action:16 
Target: poly (ADP-ribose) polymerase (PARP)
Action: inhibitor
FDA: Lynparza is an inhibitor of poly (ADP-ribose) polymerase (PARP) enzymes, including PARP1, PARP2, and PARP3.PARP enzymes are involved in normal cellular homeostasis, such as DNA transcription, cell cycle regulation, and DNArepair. Olaparib has been shown to inhibit growth of select tumor cell lines in vitro and decrease tumor growth in mousexenograft models of human cancer both as monotherapy or following platinum-based chemotherapy. Increasedcytotoxicity and anti-tumor activity following treatment with olaparib were noted in cell lines and mouse tumor modelswith deficiencies in BRCA. In vitro studies have shown that olaparib-induced cytotoxicity may involve inhibition ofPARP enzymatic activity and increased formation of PARP-DNA complex, resulting in disruption of cellular homeostasisand cell death.
3
Revlimid16 44 LENALIDOMIDE Celgene June 2013
FDA Label: Revlimid
Disease/s that Drug Treats:mantle cell lymphoma
Indications and Usage:16 REVLIMID is a thalidomide analogue indicated for the treatment of patientswith: Multiple myeloma (MM), in combination with dexamethasone (1.1). Transfusion-dependent anemia due to low- or intermediate-1-riskmyelodysplastic syndromes (MDS) associated with a deletion 5qabnormality with or without additional cytogenetic abnormalities (1.2). Mantle cell lymphoma (MCL) whose disease has relapsed or progressedafter two prior therapies, one of which included bortezomib (1.3).Limitations of Use: REVLIMID is not indicated and is not recommended for the treatmentof patients with chronic lymphocytic leukemia (CLL) outside ofcontrolled clinical trials (1.4).
DrugBank Targets:14 1. Protein cereblon;2. Tumor necrosis factor ligand superfamily member 11;3. Cadherin-5;4. Prostaglandin G/H synthase 2
Mechanism of Action:16 
Target: T cells and natural killer cells/ pro-inflammatory cytokines by monocytes
Action: activator/inhibitor
FDA: Lenalidomide is an analogue of thalidomide with immunomodulatory, antiangiogenic, and antineoplastic properties. Lenalidomide inhibitsproliferation and induces apoptosis of certain hematopoietic tumor cells including multiple myeloma, mantle cell lymphoma, and del (5q)myelodysplastic syndromes in vitro. Lenalidomide causes a delay in tumor growth in some in vivo nonclinical hematopoietic tumor modelsincluding multiple myeloma. Immunomodulatory properties of lenalidomide include activation of T cells and natural killer (NK) cells, increasednumbers of NKT cells, and inhibition of pro-inflammatory cytokines (e.g., TNF-α and IL-6) by monocytes. In multiple myeloma cells, thecombination of lenalidomide and dexamethasone synergizes the inhibition of cell proliferation and the induction of apoptosis.

Drugs for Myelodysplastic Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50)    (show all 590)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1
FludarabineapprovedPhase 4, Phase 2, Phase 3, Phase 1, Early Phase 1115421679-14-1, 75607-67-930751
Synonyms:
(2R,3S,4S,5R)-2-(6-amino-2-fluoro-9H-purin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol
(2R,3S,4S,5R)-2-(6-amino-2-fluoropurin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol
2-F-ARAA
2-F-ara-A
2-Fluoro Ara-A
2-Fluoro-9-beta-D-arabinofuranosyladenine
2-fluoro ARA-A
21679-14-1
9-beta-D-Arabinofuranosyl-2-fluoroadenine
9-beta-D-arabinofuranosyl-2-fluoro-9H-purin-6-amine
9H-Purin-6-amine, 9-beta-D-arabinofuranosyl-2-fluoro- (9CI)
AC1LCW8I
AC1Q51CF
C10H12FN5O4
CCRIS 3382
CHEMBL1568
CID657237
CPD000058874
D07966
EINECS 244-525-5
F-Ara-A
FAMP
FT-0082766
FaraA
Fludara
Fludara, Fludarabine
 
Fludarabina
Fludarabina [Spanish]
Fludarabine
Fludarabine (INN)
Fludarabine 5'-monophosphate
Fludarabine [INN]
Fludarabine monophosphate
Fludarabine phosphate
Fludarabinum
Fludarabinum [Latin]
Fludura
Fluradosa
Fluradosa (TN)
HSDB 6964
I14-4978
LS-15061
MLS000028687
NSC 118218
NSC 118218H
NSC-118218
S1491_Selleck
SAM002548956
SMR000058874
SQ Fludarabine
UNII-1X9VK9O1SC
UNII-P2K93U8740
ZINC04216238
2
Cytarabineapproved, investigationalPhase 4, Phase 3, Phase 2, Phase 11117147-94-46253
Synonyms:
(beta-D-Arabinofuranosyl)cytosine
(beta-D-arabinofuranosyl)cytosine
1-.beta.-D-arabinofuranosyl-cytosine
1-Arabinofuranosylcytosine
1-beta -D-Arabinofaranosylcytosine
1-beta -D-Arabinofuranosyl-4-amino-2(1H)pyrimidinone
1-beta -D-Arabinofuranosylcytosine
1-beta-D-Arabinofaranosylcytosine
1-beta-D-Arabinofuranosyl-4-amino-2(1H)pyrimidinone
1-beta-D-Arabinofuranosyl-Cytosine
1-beta-D-Arabinofuranosylcytosine
1-beta-D-Arabinofuranosylcytosine, Cytosine Arabinoside
1-beta-D-Arabinosyl-Cytosine
1-beta-D-Arabinosylcytosine
147-94-4
1beta -Arabinofuranasylcytosine
1beta -D-Arabinofuranosylcytosine
1beta -D-Arabinosylcytosine
1beta-Arabinofuranasylcytosine
1beta-D-Arabinofuranosylcytosine
1beta-D-Arabinosylcytosine
2(1H)-Pyrimidinone, 4-amino-1- -D-arabinofuranosyl- [CAS]
2(1H)-Pyrimidinone, 4-amino-1- -D-arabinofuranosyl
30399_FLUKA
4-Amino-1-arabinofuranosyl-2-oxo-1,2-dihydropyrimidin
4-Amino-1-arabinofuranosyl-2-oxo-1,2-dihydropyrimidin [Czech]
4-Amino-1-arabinofuranosyl-2-oxo-1,2-dihydropyrimidine
4-Amino-1-b-D-arabinofuranosyl-2-(1H)-pyrimidinone
4-Amino-1-beta-D-arabinofuranosyl-2(1H)-pyrimidinon
4-Amino-1-beta-D-arabinofuranosyl-2(1H)-pyrimidinon [Czech]
4-Amino-1-beta-D-arabinofuranosyl-2(1H)-pyrimidinone
4-amino-1-[(2R,3S,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one
4-amino-1-beta-D-arabinofuranosylpyrimidin-2(1H)-one
69-74-9 (hydrochloride)
AC-1075
AC1L1M4F
AC1Q52OJ
AI3-52329
AR3
Alexan
Ara-C
Ara-C, Cytosine Arabinoside, Cytosar-U, Cytarabine
Ara-Cytidine
AraC
Arabinocytidine
Arabinofuranosylcytosine
Arabinosyl Cytosine
Arabinosylcytosine
Arabitin
Aracytidine
Aracytin
Aracytine
Arafcyt
BIDD:GT0371
BIDD:PXR0139
BTB15125
Beta-cytosine arabinoside
C02961
C1768_SIGMA
C2035
C9H13N3O5
CCRIS 913
CHEBI:28680
CHEMBL803
CHX 3311
CID6253
CPD000449317
CYTARABINE (SEE ALSO CYTARABINE HYDROCHLORIDE 69-74-9)
Citarabina
Citarabina [INN-Spanish]
Cytarabin
Cytarabina
Cytarabine (JP15/USP/INN)
Cytarabine [USAN:INN:BAN:JAN]
 
Cytarabine liposome injection
Cytarabinoside
Cytarabinum
Cytarabinum [INN-Latin]
Cytarbel
Cytonal
Cytosar
Cytosar-U
Cytosine 1-beta-D-arabinofuranoside
Cytosine arabinofuranoside
Cytosine arabinose
Cytosine arabinoside
Cytosine arabinoside (VAN)
Cytosine beta-D-arabinofuranoside
Cytosine beta-D-arabinofuranoside hydrochloride
Cytosine beta-D-arabinoside
Cytosine, beta -D-arabinoside
Cytosine, beta-D-arabinoside
Cytosine-1-beta-D-arabinofuranoside
Cytosine-1-beta-D-arabinofuranoside hydrochloride
Cytosine-beta -D-arabinofuranoside
Cytosine-beta -arabinoside
Cytosine-beta-D-arabinofuranoside
Cytosine-beta-arabinoside
Cytosinearabinoside
D00168
DB00987
DepoCyte
Depocyt
Depocyt (TN)
Depocyt (liposomal)
Depocyte
EINECS 205-705-9
Erpalfa
FT-0082880
HMS2051K19
HMS2090A18
HSDB 3049
Intrathecal (injected into the spinal fluid) DepoCyt
Intrathecal cytarabine (also known as ara-C)
Iretin
LS-860
Lopac0_000316
MLS000758310
MLS001066340
MolPort-001-792-509
NCGC00093356-03
NCGC00093356-04
NCGC00093356-05
NCI-C04728
NSC 287459
NSC287459
S1648_Selleck
SAM001247012
SMR000449317
SR-01000075773-3
Spongocytidine
TL8001048
Tarabine
U 19920A
U-19,920
U-19920
UNII-04079A1RDZ
Udicil
ZINC03795098
beta -D-arabinosylcytosine
beta -arabinosylcytosine
beta -cytosine arabinoside
beta-Ara C
beta-Ara c
beta-Arabinosylcytosine
beta-Cytosine arabinoside
beta-D-Arabinosylcytosine
cytarabine
cytarabine liposome injection
cytosine-β-D-arabinofuranoside
3
IronapprovedPhase 4, Phase 3, Phase 2, Phase 1, Early Phase 111657439-89-623925
Synonyms:
02583_FLUKA
12310_ALDRICH
12310_RIEDEL
129048-51-7
14067-02-8
161135-39-3
190454-13-8
195161-83-2
199281-22-6
209309_ALDRICH
209309_SIAL
255637_ALDRICH
266213_ALDRICH
266256_ALDRICH
267945_ALDRICH
267953_ALDRICH
26Fe
338141_ALDRICH
356808_ALDRICH
356824_ALDRICH
356832_ALDRICH
39344-71-3
3ZhP
413054_ALDRICH
443783-52-6
44890_ALDRICH
44890_FLUKA
675141-17-0
70884-35-4
73135-38-3
7439-89-6
8011-79-8
8053-60-9
AC1L2N38
ATW 230
ATW 432
Ancor B
Ancor en 80/150
Armco iron
Atomel 28
Atomel 300M200
Atomel 500M
Atomel 95
Atomiron 44MR
Atomiron 5M
Atomiron AFP 25
Atomiron AFP 5
C00023
C3518_SIAL
C3518_SIGMA
CCRIS 1580
CHEBI:18248
CID23925
Carbonyl iron
Copy Powder CS 105-175
D007501
DB01592
DSP 1000
DSP 128B
DSP 135
DSP 135C
DSP 138
Diseases (animal), iron overload
Diseases, iron overload
EF 1000
EF 250
EFV 200/300
EFV 250
EFV 250/400
EINECS 231-096-4
 
Ed-In-Sol
Eisen
Electrolytic iron
F 60 (metal)
FE
FT 3 (element)
Fe
Fe-40
Fe1+
Feronate
Ferretts
Ferro-Caps
Ferro-Time
Ferrousal
Ferrovac E
Ferrum
Ferrum metallicum
GS 6
HF 2 (element)
HL (iron)
HQ (metal)
HS (iron)
HS 4849
HSDB 604
Hemocyte
Hierro
Hoeganaes ATW 230
Hoeganaes EH
IRMM524A_FLUKA
IRMM524B_FLUKA
IRON
Iron (Fe)
Iron (Fe1+)
Iron ion (Fe+)
Iron ion(1+)
Iron monocation
Iron powder
Iron standard for AAS
Iron(1+)
Iron(1+) ion
Iron(III) nitrate solution
Iron, carbonyl
Iron, electrolytic
Iron, elemental
Iron, ion (Fe1+)
Iron, ion (Fe1+) (8CI,9CI)
Iron, reduced
LOHA
LS-3196
MolPort-003-925-001
NC 100
PZh-1M3
PZh-2
PZh1M1
PZh2M
PZh2M1
PZh2M2
PZh3
PZh3M
PZh4M
PZhO
Reduced iron
Remko
SUY-B 2
Siderol
UNII-E1UOL152H7
Vitedyn-Slo
Yieronia
fer
ferrous iron
hierro
4
IdarubicinapprovedPhase 4, Phase 3, Phase 2, Phase 121458957-92-942890
Synonyms:
(1S,3S)-3-Acetyl-3,5,12-trihydroxy-6,11-dioxo-1,2,3,4,6,11-hexahydronaphthacen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside
(1S,3S)-3-acetyl-3,5,12-trihydroxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside
(1s,3s)-3-acetyl-3,5,12-trihydroxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-|A-l-lyxo-hexopyranoside
(7S,9S)-9-acetyl-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-8,10-dihydro-7H-tetracene-5,12-dione
(7S-cis)-9-Acetyl-7-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,9,11-trihydroxy-5,12-naphthacenedione
4-DMD
4-Demethoxydaunomycin
4-Demethoxydaunorubicin
4-Desmethoxydaunorubicin
57852-57-0
57852-57-0 (HYDROCHLORIDE)
58957-92-9
AC1L28SA
AC1Q6JJ4
BRD-K69650333-001-01-1
C26H27NO9
CCRIS 5083
CHEBI:42068
CHEMBL1117
CID42890
D08062
DB01177
DM5
DMDR
EU-0100600
HMS2089D05
I 1656
I06-1097
I1656_SIGMA
IDARUBICIN
 
IMI 30
IMI-30
Idamycin
Idamycin PFS
Idarubicin (INN)
Idarubicin Aglycone
Idarubicin HCl PFS
Idarubicin Hcl
Idarubicin Hcl Pfs
Idarubicin Hydrochloride
Idarubicin [INN:BAN]
Idarubicina
Idarubicina [INN-Spanish]
Idarubicine
Idarubicine [INN-French]
Idarubicinum
Idarubicinum [INN-Latin]
KBioSS_002388
LS-94015
Lopac0_000600
MLS000759470
NCGC00093976-01
NCGC00093976-02
NCGC00093976-03
NCGC00093976-04
NSC-256439
NSC256439
SMR000466355
UNII-ZRP63D75JW
Zavedos
Zavedos (TN)
idarubicin hydrochloride
5
VidarabineapprovedPhase 4, Phase 3, Phase 1, Phase 2, Early Phase 152124356-66-932326, 21704
Synonyms:
(+)-Cyclaradine
.beta.-Adenosine
.beta.-D-Adenosine
1odi
2-(6-AMINO-purin-9-yl)-5-hydroxymethyl-tetrahydro-furan-3,4-diol
2946-52-3
2fqy
2gl0
30143-02-3
3080-29-3
3228-71-5
4005-33-8
46946-45-6
46969-16-8
524-69-6
5536-17-4
58-61-7
9-Arabinosyladenine
9-beta-D-Arabinofuranosyl-9H-purin-6-amine
9-beta-D-Arabinofuranosyl-adenine
9-beta-D-Arabinofuranosyladenine
9-beta-D-arabinofuranosyl-adenine
9-β-D-arabinofuranosyl-9H-purin-6-amine
9-β-D-arabinofuranosyladenine
A 9251
A0152
A4036_SIGMA
A4676_SIGMA
A5762_SIGMA
A9251_SIGMA
AC1L18OL
AC1L1U8O
AC1L2IWM
AC1L2SCM
AC1O4WIN
AC1O8PY7
AC1Q1ID3
AC1Q4Y1Z
AC1Q52XU
ADENOSINE, U.S.P.
ADN
AI3-52413
AI3-52821
AR-1H6029
ARA-A NSC 247519
Ade-Rib
Adenine Arabinoside
Adenine arabinoside
Adenine nucleoside
Adenine riboside
Adenine xyloside
Adenocard
Adenocard (TN)
Adenocard, Adenosine
Adenocor
Adenoscan
Adenoscan (TN)
Adenosin
Adenosin [German]
Adenosine (JAN/USP)
Adenosine [USAN:BAN]
Adenosine arabinose
Adenosine-8-14C
Adensoine
Ambap5536-17-4
Ara A
Ara-A
Ara-ATP
Araadenosine
Arabinoside Adenine
Arabinoside adenine
Arabinosyl Adenine
Arabinosyl adenine
Arabinosyl-adenine
Arabinosyladenine
Arasena-A
Armes
Armes (TN)
BB_NC-0565
BPBio1_000898
BRN 0624881
BSPBio_000816
BSPBio_001796
BSPBio_002000
Bio1_000437
Bio1_000926
Bio1_001415
Boniton
C00212
CAS-5536-17-4
CCRIS 2557
CCRIS 3383
CHEBI:136932
CHEBI:16335
CHEBI:45327
CHEMBL1090
CHEMBL20247
CHEMBL477
CI 673
CI-673
CID102198
CID191
CID21704
CID60961
CID6420052
CID6713976
CPD000471872
Caswell No. 010B
D000241
D00045
D06298
DB00640
DivK1c_000191
EINECS 200-389-9
EINECS 217-911-6
EINECS 226-893-9
EU-0100123
FT-0082881
HMS1570I18
HMS1920A13
HMS1921K05
HMS2090F06
HMS2091G13
HMS2092C16
HMS500J13
HSDB 6514
 
I01-1121
IDI1_000191
KBio1_000191
KBio2_002418
KBio2_004986
KBio2_007554
KBio3_001296
KBio3_001500
KBioGR_001224
KBioSS_002424
L000094
LS-15059
LS-15085
Lopac0_000123
MEDR-640
MLS000069638
MLS000699527
MLS001066352
MLS001333133
MLS001333134
MLS002153227
MLS002153992
MolPort-001-785-903
MolPort-001-838-229
MolPort-003-666-308
Myocol
NCGC00016656-01
NCGC00023673-03
NCGC00023673-04
NCGC00023673-05
NCGC00023673-06
NCGC00023673-07
NCGC00094579-01
NCGC00094579-02
NCGC00094579-03
NCGC00094579-04
NCGC00178869-01
NCGC00179417-01
NCI60_003823
NCI60_037192
NCIOpen2_003303
NCIOpen2_005376
NINDS_000191
NSC 247519
NSC 404241
NSC 627048
NSC 7359
NSC 7652
NSC-404241
NSC247519
NSC404241
NSC627048
NSC70422
NSC7359
NSC7652
NSC80832
NSC87676
NSC91041
Nucleocardyl
PDSP1_001036
PDSP2_001020
Pallacor
Polyadenosine
Polyriboadenosine
Prestwick0_000768
Prestwick1_000768
Prestwick2_000768
Prestwick3_000768
Prestwick_983
RAB
S1647_Selleck
S1784_Selleck
SAM002564191
SMP1_000312
SMR000058216
SMR000225041
SMR000471872
SMR001233326
SPBio_001194
SPBio_001491
SPBio_002755
SPECTRUM1500107
SPECTRUM1500609
SR 96225
SR-96225
STK361815
SUN-Y4001
Sandesin
Spectrum2_001257
Spectrum2_001336
Spectrum3_000288
Spectrum3_000580
Spectrum4_000782
Spectrum5_001429
Spectrum_001894
Spongoadenosine
TL8003749
UNII-3XQD2MEW34
UNII-K72T3FS567
USAF CB-10
V0098
VIRDARABINE
Vidarabin
Vidarabina
Vidarabina [DCIT]
Vidarabine
Vidarabine (JAN)
Vidarabine anhydrous
Vidarabinum
Vira ATM
Vira-A
Vira-A, Vidarabine
XA
Xylosyl A
Xylosyladenine
ZINC00970363
ZINC02169830
adenine-D-ribose
adenosine
alpha-Ara A
beta-Adenosine
beta-Ara A
beta-D-Adenosine
bmse000061
nchembio.143-comp9
nchembio.186-comp109
nchembio.64-comp4
nchembio706-5
6
ThiotepaapprovedPhase 4, Phase 3, Phase 2, Phase 122652-24-45453
Synonyms:
 
Thioplex
7
LenograstimapprovedPhase 4, Phase 2, Phase 3, Phase 11220135968-09-1
Synonyms:
G-CSF (CHO cell derived)
Glycosylated recombinant G-CSF
Glycosylated recombinant granulocyte colony stimulating factor
 
Granulocyte colony stimulating factor 3 (CHO cell derived)
Granulocyte colony-stimulating factor lenograstim
Lenograstim (genetical recombination)
Lenograstim rDNA
8
Cyclophosphamideapproved, investigationalPhase 4, Phase 3, Phase 2, Phase 1, Early Phase 1293550-18-0, 6055-19-22907
Synonyms:
(+-)-Cyclophosphamide
(-)-Cyclophosphamide
(RS)-Cyclophosphamide
1-(bis(2-chloroethyl)amino)-1-oxo-2-aza-5-oxaphosphoridine
1-Bis(2-chloroethyl)amino-1-oxo-2-aza-5-oxaphosphoridin
2-[Bis(2-chloroethylamino)]-tetrahydro-2H-1,3,2-oxazaphosphorine-2-oxide
4-Hydroxy-cyclophosphan-mamophosphatide
50-18-0
60007-95-6
6055-19-2 (monohydrate)
75526-90-8
AC1L1EQQ
AI3-26198
ASTA
ASTA B518
Anhydrous cyclophosphamide
Asta B 518
B 518
B-518
BRN 0011744
BSPBio_002099
Bis(2-chloroethyl)phosphoramide cyclic propanolamide ester
C 0768
C07888
C7H15Cl2N2O2P
CB 4564
CB-4564
CCRIS 188
CHEBI:4027
CHEMBL32520
CHEMBL88
CID2907
CP
CPA
CTX
CY
Ciclofosfamida
Ciclofosfamida [INN-Spanish]
Ciclofosfamide
Ciclophosphamide
Ciclophosphamide [INN]
Clafen
Claphene
Cycloblastin
Cyclophosphamid
Cyclophosphamide
Cyclophosphamide (INN)
Cyclophosphamide (TN)
Cyclophosphamide (anhydrous form)
Cyclophosphamide (anhydrous)
Cyclophosphamide Monohydrate
Cyclophosphamide Sterile
Cyclophosphamide anhydrous
Cyclophosphamide, (+-)-Isomer
Cyclophosphamides
Cyclophosphamidum
Cyclophosphamidum [INN-Latin]
Cyclophosphan
Cyclophosphane
Cyclophosphanum
Cyclophosphoramide
Cyclostin
Cyklofosfamid
Cyklofosfamid [Czech]
Cytophosphan
Cytophosphane
Cytoxan
Cytoxan (TN)
Cytoxan Lyoph
D,L-Cyclophosphamide
D07760
 
DB00531
DivK1c_000246
EINECS 200-015-4
EU-0100238
Endoxan
Endoxan R
Endoxan-Asta
Endoxana
Endoxanal
Endoxane
Enduxan
Genoxal
HMS2090A12
HSDB 3047
Hexadrin
IDI1_000246
KBio1_000246
KBio2_001338
KBio2_003906
KBio2_006474
KBio3_001319
KBioGR_000888
KBioSS_001338
LS-1302
LS-99787
Ledoxina
Lopac-C-0768
Lopac0_000238
Lyophilized Cytoxan
Mitoxan
MolPort-001-783-420
N,N-Bis(2-chloroethyl)-1,3,2-oxazaphosphinan-2-amine 2-oxide
N,N-Bis(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorin-2-amine 2-oxide
NCGC00015209-01
NCGC00015209-03
NCGC00015209-06
NCGC00091741-02
NCGC00091741-03
NCI-C04900
NCI60_002097
NINDS_000246
NSC 26271
NSC-26271
NSC26271
NSC273033
NSC273034
Neosar
Occupation, cyclophosphamide exposure
Procytox
RCRA waste no. U058
Rcra Waste Number U058
Rcra waste number U058
Revimmune
S1217_Selleck
SK 20501
SPBio_001071
STK177249
STOCK2S-91217
Semdoxan
Sendoxan
Senduxan
Spectrum2_001146
Spectrum3_000370
Spectrum4_000304
Spectrum5_000795
Spectrum_000858
UNII-6UXW23996M
WLN: T6MPOTJ BO BN2G2G
Zyklophosphamid
Zyklophosphamid [German]
bis(2-Chloroethyl)phosphami de cyclic propanolamide
bis(2-Chloroethyl)phosphamide cyclic propanolamide ester
cyclophosphamide
9
Miconazoleapproved, investigational, vet_approvedPhase 4, Phase 3, Phase 2, Phase 1370622916-47-84189
Synonyms:
(+-)-1-(2,4-Dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl)imidazole
1-(2,4-Dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl)imidazole
1-(2,4-dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl) imidazole
1-[2,4-Dichloro- beta-([2,4-dichloro- benzyl]oxy)phenethyl]imidazole
1-[2-(2,4-Dichloro-benzyloxy)-2-(2,4-dichloro-phenyl)-ethyl]-1H-imidazole
1-[2-(2,4-Dichlorophenyl)-2-[(2,4-dichlorophenyl)methoxy]ethyl]-1H-imidazole
1-[2-(2,4-dichlorobenzyloxy)-2-(2,4-dichlorophenyl)ethyl]-1H-imidazole
1-[2-(2,4-dichlorophenyl)-2-[(2,4-dichlorophenyl)methoxy]ethyl]imidazole
1-[2-(2,4-dichlorophenyl)-2-{[(2,4-dichlorophenyl)methyl]oxy}ethyl]-1H-imidazole
1-{2-[(2,4-dichlorobenzyl)oxy]-2-(2,4-dichlorophenyl)ethyl}-1H-imidazole
22832-87-7 (NITRATE)
22916-47-8
75319-47-0
AB00053500
AC1L1HM1
AKOS001574474
Aflorix(nitrate)
Albistat(nitrate)
Andergin(nitrate)
BPBio1_000279
BRD-A82396632-001-03-0
BRD-A82396632-008-02-7
BRN 0965511
BSPBio_000253
BSPBio_002033
CCRIS 7924
CHEBI:6923
CHEMBL91
CID4189
CPD-4501
Conofite(nitrate)
D00416
DB01110
Dactarin
Daktarin IV
Daktarin iv
DivK1c_000156
EINECS 245-324-5
Epi-Monistat(nitrate)
Femizol-M
Florid(nitrate)
Gyno-Daktar(nitrate)
HMS1568M15
HMS2090B21
I14-14342
IDI1_000156
Imidazole, 1-(2-(2,4-dichlorophenyl)-2-((2,4-dichlorophenyl)methoxy)ethyl)- (9CI)
KBio1_000156
KBio2_001445
KBio2_004013
KBio2_006581
KBio3_001533
KBioGR_000581
KBioSS_001445
LS-78378
Lotrimin AF(nitrate)
MCZ
MJR 1762
MLS002222203
Micantin (nitrate)
Miconasil Nitrate
 
Miconazol
Miconazol [INN-Spanish]
Miconazole
Miconazole (JP15/USP/INN)
Miconazole 3
Miconazole 3 Combination Pack
Miconazole 7 Combination Pack
Miconazole [USAN:BAN:INN:JAN]
Miconazole nitrate salt
Miconazole-7
Miconazolo
Miconazolo [DCIT]
Miconazolum
Miconazolum [INN-Latin]
Micozole
Minostate
MolPort-002-557-553
Monazole 7
Monista (nitrate)
Monistat
Monistat (TN)
Monistat 1 Combination Pack
Monistat 3 Dual-Pak
Monistat 3 Vaginal Ovules
Monistat 5 Tampon
Monistat 7 Dual-Pak
Monistat 7 Vaginal Suppositories
Monistat Dual- PAK
Monistat IV
Monistat iv (TN)
Monistat iv (tn)
Monistat-Derm
NCI60_001353
NCI60_001380
NINDS_000156
NSC 170986
NSC169434
NSC170986
Novo-Miconazole Vaginal Ovules
Oprea1_091955
Prestwick0_000067
Prestwick1_000067
Prestwick2_000067
Prestwick3_000067
Prestwick_335
R 18134
R-14,889
SMR001307249
SPBio_000976
SPBio_002174
STK834405
STOCK1S-93556
Spectrum2_001048
Spectrum3_000507
Spectrum4_000061
Spectrum5_001297
Spectrum_000965
UNII-7NNO0D7S5M
Vusion
Zimycan
imidazole, 1-(2-(2,4-dichlorophenyl)-2-((2,4-dichlorophenyl) methoxy)ethyl)- (9CI)
miconazole
10
Busulfanapproved, investigationalPhase 4, Phase 3, Phase 2, Phase 1, Early Phase 154555-98-12478
Synonyms:
1, 4-Dimethanesulfonoxybutane
1, 4-Dimethylsulfonoxybutane
1, {4-Bis[methanesulfonoxy]butane}
1,4-BUTANEDIOL DIMETHANESULFONATE
1,4-Bis(methanesulfonoxy)butane
1,4-Bis(methanesulfonyloxy)butane
1,4-Bis[methanesulfonoxy]butane
1,4-Butanedi yl dimethanesulfonate
1,4-Butanediol dimethanesulfonate
1,4-Butanediol dimethanesulphonate
1,4-Butanediol dimethylsulfonate
1,4-Butanediol, dimethanesulfonate
1,4-Butanediol, dimethanesulphonate
1,4-Butanediyl dimethanesulfonate
1,4-Di(methylsulfonoxy)butane
1,4-Dimesyloxybutane
1,4-Dimethane sulfonyl oxybutane
1,4-Dimethanesulfonoxybutane
1,4-Dimethanesulfonoxylbutane
1,4-Dimethanesulfonyloxybutane
1,4-Dimethanesulphonyloxybutane
1,4-Dimethylsulfonoxybutane
1,4-Dimethylsulfonyloxybutane
2041 C. B
2041 C. B.
2041 C.B
2041 C.B.
4-((Methylsulfonyl)oxy)butyl methanesulfonate
4-methylsulfonyloxybutyl methanesulfonate
55-98-1
AC-198
AC1L1DRQ
AC1Q4GRQ
AI3-25012
AKOS003614975
AN 33501
Ambap55-98-1
B1022
B2635_FLUKA
B2635_SIGMA
BRN 1791786
BSPBio_001920
BUSULFAN (1,4-BUTANEDIOL, DIMETHANESULFONATE)
Bisulfex
Busilvex
Busulfan
Busulfan (JP15/USP/INN)
Busulfan GlaxoSmithKline Brand
Busulfan Orphan Brand
Busulfan Wellcome
Busulfan Wellcome Brand
Busulfan [INN:JAN]
Busulfano
Busulfano [INN-Spanish]
Busulfanum
Busulfanum [INN-Latin]
Busulfex
Busulphan
Busulphane
Butanedioldimethanesulfonate
Buzulfan
C.B. 2041
C6H14O6S2
CB 2041
CCRIS 418
CHEBI:28901
CHEMBL820
CID2478
CPD000058613
Citosulfan
D002066
D00248
DB01008
DivK1c_000847
EINECS 200-250-2
FT-0083567
G.T. 41
GT 2041
GT 41
Glaxo Wellcome Brand of Busulfan
GlaxoSmithKline Brand of Busulfan
Glyzophrol
HMS1920I07
HMS2091O09
HMS502K09
 
HSDB 7605
I09-1371
IDI1_000847
InChI=1/C6H14O6S2/c1-13(7,8)11-5-3-4-6-12-14(2,9)10/h3-6H2,1-2H3
KBio1_000847
KBio2_000512
KBio2_003080
KBio2_005648
KBio3_001420
KBioGR_000698
KBioSS_000512
LS-1358
Leucosulfan
MLS001076666
MYLERAN (TN)
Mablin
Methanesulfonic
Methanesulfonic acid, tetram ethylene ester
Methanesulfonic acid, tetramethylene ester
Mielevcin
Mielosan
Mielucin
Milecitan
Mileran
Misulban
Mitosan
Mitostan
MolPort-001-783-406
Myeleukon
Myeloleukon
Myelosan
Myelosanum
Mylecytan
Myleran
Myleran Tablets
Myleran tablets
Myleran, Busulfex, Busulfan
Mylerlan
NCGC00090905-01
NCGC00090905-02
NCGC00090905-03
NCGC00090905-04
NCGC00090905-05
NCGC00090905-06
NCGC00090905-07
NCI-C01592
NCI60_041640
NCIMech_000192
NINDS_000847
NSC 750
NSC-750
NSC-750sulphabutin
NSC750
Orphan Brand of Busulfan
Prestwick_989
S1692_Selleck
SAM002554887
SMR000058613
SPBio_000253
SPECTRUM1500152
ST50825921
Spectrum2_000067
Spectrum3_000320
Spectrum4_000259
Spectrum5_000928
Spectrum_000092
Sulfabutin
Sulfabutin (VAN)
Sulphabutin
Tetramethylene Dimethane Sulfonate
Tetramethylene bis(methanesulfonate)
Tetramethylene bis[methanesulfonate]
Tetramethylene dimethane sulfonate
Tetramethylene {bis[methanesulfonate]}
Tetramethylenester Kyseliny Methansulfonove
Tetramethylenester kyseliny methansulfonove
Tetramethylenester kyseliny methansulfonove [Czech]
UNII-G1LN9045DK
WLN: WS1&O4OSW1
Wellcome Brand of Busulfan
Wellcome, Busulfan
X 149
acid, tetramethylene ester
alkylating agent: crosslinks guanine residues
busulfan
butane-1,4-diyl dimethanesulfonate
n-Butane-1,3-di(methylsulfonate)
11
Cyclosporineapproved, investigational, vet_approvedPhase 4, Phase 3, Phase 2, Phase 192279217-60-0, 59865-13-35284373, 6435893
Synonyms:
1c5f
1cyn
30024_FLUKA
30024_SIGMA
59865-13-3
79217-60-0
AC1L1EQW
AC1NQXJE
AC1NR4C4
AC1NUQK3
AC1NUZNC
AC1O5KOG
AC1Q2UDG
Ambap59865-13-3
Ambotz59865-13-3
Antibiotic S 7481F1
BMT-ABA-SAR-MLE-VAL-MLE-ALA-ALA-MLE-MLE-MVA
BMT-ABA-SAR-MLE-VAL-MLE-ALA-DAL-MLE-MLE-MVA
BPBio1_000496
BRD-A64290322-001-01-6
BRD-A69815203-001-04-3
BRD-K13533483-001-03-0
BSPBio_000450
BSPBio_001596
BSPBio_003186
C 3662
C05086
C1832_SIGMA
C3662_SIGMA
C62H111N11O12
CB-01-09 MMX
CHEBI:106343
CHEBI:328305
CHEBI:4031
CHEMBL160
CHEMBL386389
CHEMBL532318
CID2909
CID5280754
CID5284373
CID5458585
CID5497195
CID6435893
CSA
CYCLOSPORIN A (SEE ALSO TRANSGENIC MODEL EVALUATION (CYCLOSPORIN A))
CYCLOSPORIN A, USP
Ciclosporin
Ciclosporin (JP15)
Ciclosporina
Ciclosporine
Ciclosporinum
Cipol N
Cipol-N
Consupren
Consupren S
CsA
CsA & IFN.alpha.
CyA
Cyclokat
Cyclosporin
Cyclosporin A
Cyclosporin A & IFN.alpha.
Cyclosporin A Implant
Cyclosporin A, Tolypocladium inflatum
Cyclosporine (USP)
Cyclosporine A
Cyclosporine [USAN]
D00184
DE-076
DivK1c_000871
EU-0100242
Equoral
GNF-Pf-2808
Gengraf
Gengraf (TN)
HMS1569G12
HMS1791P18
HMS1921L20
HMS1989P18
HMS2089A09
HMS2092F06
HMS502L13
Helv Chim Acta 60: 1568 (1977)
 
I06-0379
I06-0966
IDI1_000871
KBio1_000871
KBio2_000780
KBio2_003348
KBio2_005916
KBio3_002686
KBioGR_001898
KBioSS_000780
LMPK14000003
LS-257
LS-58836
Lopac0_000242
MLS000028376
MLS001333756
MLS002153454
MLS002207033
Mitogard
Modusik-A
MolPort-000-760-988
MolPort-005-934-008
MolPort-006-705-994
NCGC00093704-01
NCGC00093704-02
NCGC00093704-03
NCGC00093704-04
NCGC00093704-05
NCGC00093704-06
NCGC00093704-07
NCGC00093704-08
NCGC00164258-01
NCGC00164258-02
NINDS_000871
NSC290193
Neoplanta
Neoral
Neoral (TN)
NeuroSTAT
Nova-22007
OL 27-400
OL-27400
OLO-400
Papilock
Prestwick2_000435
Prestwick3_000435
Prestwick_731
Pulminiq
Ramihyphin A
Restasis
Restasis (TN)
S-Neoral
S1514_Selleck
SDZ-OXL 400
SMR000058578
SPBio_001467
SPECTRUM1502202
ST-603
Sandimmun
Sandimmun Neoral
Sandimmune
Sandimmune (TN)
Sandimmune, Gengraf, Restasis, Atopica, Sangcya, Cyclosporine
Sang-2000
Sang-35
SangCyA
Sangcya
Sigmasporin
Sigmasporin Microoral
Spectrum2_001484
Spectrum3_001593
Spectrum4_001279
Spectrum5_001628
Spectrum_000300
TRANSGENIC MODEL EVALUATION (CYCLOSPORIN A)
Vekacia
Zyclorin
cyclophorine
cyclosporin A
cyclosporine
from Tolypocladium inflatum (Trichoderma polysporin)
nchembio.184-comp6
nchembio.301-comp5
nchembio.342-comp1
12
Azacitidineapproved, investigationalPhase 4, Phase 3, Phase 2, Phase 1529320-67-29444
Synonyms:
2-(beta-D-Ribofuranosyl)-4-amino-1,3,5-triazin-2-one
320-67-2
4-Amino-1-(beta-D-ribofuranosyl)-1,3,5-triazin-2(1H)-one
4-Amino-1-beta-D-ribofuranosyl-1,3,5-traizin-2(1H)-one
4-Amino-1-beta-D-ribofuranosyl-1,3,5-triazine-2(1H)-one
4-Amino-1-beta-D-ribofuranosyl-S-triazin-2(1H)-one
4-Amino-1-beta-D-ribofuranosyl-s-triazin-2(1H)-one
4-Amino-1-beta-d-ribofuranosyl-1,3,5-triazin-2(1H)-one
4-amino-1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,3,5-triaz
4-amino-1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,3,5-triazin-2-one
4-amino-1-beta-L-ribofuranosyl-1,3,5-triazin-2(1H)-one
5 AZC
5 Azacytidine
5-AC
5-AZAC
5-AZCR
5-Azacytidine
5-aza-CR
5-azacitidine
5-azacytidine
5-azacytidine, Mylosar, Ladakamycin, Vidaza, Azacitidine
5AzaC
A 2385
A1287_SIGMA
A2385_SIGMA
AC1L1T1Y
Antibiotic U 18496
Azacitidina
Azacitidina [INN-Spanish]
Azacitidine
Azacitidine (JAN/USAN/INN)
Azacitidine [USAN:INN]
Azacitidinum
Azacitidinum [INN-Latin]
Azacytidine
BCBcMAP01_000083
BRN 0620461
BSPBio_003157
C11262
CCRIS 60
CHEBI:2038
CHEMBL1489
CID9444
CPD000857239
D001374
D03021
DB00928
DivK1c_000125
EINECS 206-280-2
EU-0100035
FT-0081170
HMS1921J22
HMS2092D08
HMS500G07
HSDB 6879
IDI1_000125
InChI=1/C8H12N4O5/c9-7-10-2-12(8(16)11-7)6-5(15)4(14)3(1-13)17-6/h2-6,13-15H,1H2,(H2,9,11,16)/t3-,4-,5-,6-/m1/s1
 
Jsp005945
KBio1_000125
KBio2_001742
KBio2_002556
KBio2_004310
KBio2_005124
KBio2_006878
KBio2_007692
KBio3_002657
KBio3_003034
KBioGR_001444
KBioGR_002556
KBioSS_001742
KBioSS_002565
LS-1189
Ladakamycin
Lopac0_000035
MLS001333121
MLS001333122
MLS002153249
MolMap_000062
Mylosar
NCGC00090851-01
NCGC00090851-02
NCGC00090851-03
NCGC00090851-04
NCGC00090851-08
NCGC00178234-01
NCI-C01569
NINDS_000125
NS-17
NSC 102816
NSC-102816
NSC102816
Pharmion Brand of Azacitidine
S1782_Selleck
SAM002264595
SMR000857239
SPBio_000892
SPECTRUM1502111
ST056940
Spectrum2_000786
Spectrum3_001509
Spectrum4_000922
Spectrum5_001166
Spectrum_001262
TL80073599
U 18496
U-18496
UNII-M801H13NRU
Vidaza
Vidaza (TN)
WR-183027
ZINC03861768
cMAP_000082
mylo sar
pyrimidine antimetabolite: inhibits nucleic acid replication
s-Triazin-2(1H)-one, 4-amino-1-beta-D-ribofuranosyl- (8CI)
wr 183027
13
Decitabineapproved, investigationalPhase 4, Phase 3, Phase 2, Phase 12442353-33-5451668
Synonyms:
-Deoxycytidine
-azacytidine
2'-Deoxy-5-azacytidine
2353-33-5
4-Amino-1-(2-deoxy-beta-D-erythro-pentofuranosyl)-1,3,5-triazin-2(1H)-one
4-Amino-1-(2-deoxy-beta-D-erythro-pentofuranosyl)-s-triazin-2(1H)-one
4-Amino-1-(2-deoxy-beta-D-ribofuranosyl)-1,3,5-triazin-2(1H)-one
4-amino-1-(2-Deoxy-beta-D-erythro-pentofuranosyl)-S-triazin-2(1H)-one
4-amino-1-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,3,5-triazin-2-one
5-AZAdC
5-Aza-2&prime
5-Aza-2'-deoxycytidine
5-Azadeoxycytidine
5-Deoxy-2&prime
5-aza-2'-deoxycytidine
5-aza-2-deoxycytidine
5-aza-CdR
5-aza-dC
5A2dc
A3656_SIGMA
AC-1135
AC1L9PS9
AzadC
 
Azadc
CHEBI:50131
CHEMBL1201129
CID451668
D03665
DB01262
Dacogen
Dacogen (TN)
Dacogen, 5-aza-2'-deoxycytidine,NSC 127716, Dacogen, DAC, Decitabine
Decitabine
Decitabine (USAN/INN)
Dezocitidine
E-7373
FT-0082622
MLS001332587
MLS001332588
MolMap_000063
NCGC_5ADOC
NSC-127716
NSC127716
S1200_Selleck
SBB066121
SMR000857076
TL8001944
14
Micafunginapproved, investigationalPhase 4, Phase 258235114-32-63081921, 477468
Synonyms:
5-[(1S,2S)-2-{(2R,6S,9S,11R,12R,14aS,15S,16S,20S,23S,25aS)-20-[(1R)-3-amino-1-hydroxy-3-oxopropyl]-2,11,12,15-tetrahydroxy-6-[(1R)-1-hydroxyethyl]-16-methyl-5,8,14,19,22,25-hexaoxo-9-[(4-{5-[4-(pentyloxy)phenyl]isoxazol-3-yl}benzoyl)amino]tetracosahydro-1H-dipyrrolo[2,1-c:2',1'-l][1,4,7,10,13,16]hexaazacyclohenicosin-23-yl}-1,2-dihydroxyethyl]-2-hydroxyphenyl hydrogen sulfate
5.1:6-anhydro{(4R,5R)-4,5-dihydroxy-N(2)-(4-{5-[4-(pentyloxy)phenyl]isoxazol-3-yl}benzoyl)-L-ornithyl-L-threonyl-(4R)-4-hydroxy-L-prolyl-(4S)-4-hydroxy-4-[4-hydroxy-3-(sulfooxy)phenyl]-L-threonyl-(3R)-3-hydroxy-L-glutaminyl-(3S,4S)-3-hydroxy-4-methyl-L-proline}
AC-6107
AC1L9WY8
AC1MIXSV
CHEBI:600520
CHEMBL1201351
CID11804463
CID3081921
CID477468
 
CID6602291
DB01141
FK-463
FK463
I14-11710
LS-184079
LS-187369
Micafungin
Mycamine
Mycamine(TM)
UNII-R10H71BSWG
15
TazobactamapprovedPhase 4, Phase 310389786-04-9123630
Synonyms:
(2S,3S,5R)-3-methyl-4,4,7-trioxo-3-(triazol-1-ylmethyl)-4
(2S,3S,5R)-3-methyl-7-oxo-3-(1H-1,2,3-triazol-1-ylmethyl)-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid 4,4-dioxide
89785-84-2
89786-04-9
AC-7620
AC1L3X07
BIDD:GT0212
C07771
CHEBI:100207
CHEMBL404
 
CID123630
CL-298741
CL298741
D00660
DB01606
MolPort-002-500-123
TAZ
Tazobactam
Tazobactam (JAN/USAN/INN)
YTR-830H
YTR830H
16
Deferasiroxapproved, investigationalPhase 4, Phase 3, Phase 289201530-41-85493381
Synonyms:
Deferasiroxum
Deferasiroxum [inn-latin]
 
Exjade
ICL 670
ICL 670a
deferasirox
17
PiperacillinapprovedPhase 4, Phase 310166258-76-243672
Synonyms:
(2S,5R,6R)-6-[[(2R)-2-[(4-ethyl-2,3-dioxopiperazine-1-carbonyl)amino]-2-phenylacetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid
(2S,5R,6R)-6-{[(2R)-2-{[(4-ethyl-2,3-dioxopiperazin-1-yl)carbonyl]amino}-2-phenylacetyl]amino}-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid
(2S-(2alpha,5alpha,6beta(S*)))-6-(((((4-Ethyl-2,3-dioxopiperazin-1-yl)carbonyl)amino)phenylacetyl)amino)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid
4-ethyl-2,3-dioxopiperazine carbonyl ampicillin
59703-84-3
59703-84-3 (mono-hydrochloride salt)
6-(D-(-)-alpha-(4-Ethyl-2,3-dioxo-1-piperazinecarboxamido)phenylacetamido)penicillanic acid
61477-96-1
6beta-{(2R)-2-[(4-ethyl-2,3-dioxopiperazin-1-yl)carboxamido]-2-phenylacetamido}-2,2-dimethylpenam-3alpha-carboxylic acid
AC1L2ACR
AC1Q5QXJ
BIDD:GT0167
BPBio1_000848
BRD-K86873305-236-03-0
BSPBio_000770
C14034
C23H27N5O7S
CCRIS 7362
CHEBI:8232
CHEMBL702
CID43672
Cl-227193
D08380
EINECS 262-811-8
HMS2090H19
LS-149794
 
PIPC
PIPERACILLIN SODIUM
Peperacillin
Peracin
Peracin (TN)
Piperacilina
Piperacillin
Piperacillin (INN)
Piperacillin (anhydrous)
Piperacillin Anhydrous
Piperacillin Monosodium Salt
Piperacillin anhydrous
Piperacillina
Piperacillinum
Pipercillin
Pipracil
Pipracil, Piper
Pipril
Pipéracilline
Prestwick0_000755
Prestwick1_000755
Prestwick2_000755
Prestwick3_000755
SPBio_002709
T-1220
UNII-9I628532GX
piperacillin
18
Posaconazoleapproved, investigational, vet_approvedPhase 4, Phase 3, Phase 2, Phase 156171228-49-2147912
Synonyms:
1-((1S,2S)-1-Ethyl-2-hydroxypropyl)-4-{4-[4-(4-{[(5S,3R)-5-(2,4-difluorophenyl)-5-(1,2,4-triazolylmethyl)oxolan-3-yl]methoxy}phenyl)piperazinyl]phenyl}-1,2,4-triazolin-5-one
171228-49-2
177571-33-4
4-(p-(4-(p-(((3R,5R)-5-(2,4-Difluorophenyl)tetrahydro-5-(1H-1,2,4-triazol-1-ylmethyl)-3-furyl)methoxy)phenyl)-1-piperazinyl)phenyl)-1-((1S,2S)-1-ethyl-2-hydroxypropyl)-delta(sup 2)-1,2,4-triazolin-5-one
4-[4-[4-[4-[[(3R,5R)-5-(2,4-difluorophenyl)-5-(1,2,4-triazol-1-ylmethyl)oxolan-3-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-2-[(2S,3S)-2-hydroxypentan-3-yl]-1,2,4-triazol-3-one
4-[4-[4-[4-[[(5R)-5-(2,4-difluorophenyl)-5-(1,2,4-triazol-1-ylmethyl)oxolan-3-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-2-[(2S,3S)-2-hydroxypentan-3-yl]-1,2,4-triazol-3-one
AC-1350
AC1L3W34
AC1LAHLQ
AKOS005145917
CHEBI:434337
CHEMBL1397
CHEMBL371938
CHEMBL371939
CID10532764
CID11520437
CID11542142
CID147912
CID468595
D02555
 
DB01263
HSDB 7421
LS-186118
LS-186988
LS-187630
MolPort-006-666-426
Noxafil
Noxafil (TN)
Noxafil, Posaconazole
Posaconazole
Posaconazole (USAN/INN)
Posaconazole SP
Posaconazole [USAN:INN:BAN]
Posaconazole in combination with MGCD290
S1257_Selleck
SCH-56592
SCH56592
Sch 56592
Spriafil
UNII-6TK1G07BHZ
X2N
posaconazole
19
Radium Ra 223 dichlorideapproved, investigationalPhase 458444811-40-9
Synonyms:
Radium-223 chloride
 
Radium-223 dichloride
Xofigo
20
SuccinylcholineapprovedPhase 4169306-40-15314
Synonyms:
2,2'-[(1,4-DIOXOBUTANE-1,4-DIYL)BIS(OXY)]BIS(N,N,N-TRIMETHYLETHANAMINIUM)
2,2'-[(1,4-DIOXOBUTANE-1,4-diyl)bis(oxy)]bis(N,N,N-trimethylethanaminium)
2ha2
2ha6
306-40-1
4-04-00-01451 (Beilstein Handbook Reference)
541-19-5 (diiodide)
55-94-7 (dibromide)
71-27-2 (dichloride)
AC1L1K2T
Anectine
BRN 1805311
C07546
C14H30N2O4
CHEBI:45652
CHEMBL703
CID5314
Choline, succinate (2:1) (ester)
Choline, succinate (ester)
DB00202
Diacetylcholine
Dicholine succinate
Ditilin
Ditiline
HMS2090P14
HSDB 3254
InChI=1/C14H30N2O4/c1-15(2,3)9-11-19-13(17)7-8-14(18)20-12-10-16(4,5)6/h7-12H2,1-6H3/q+2
L000926
LS-53328
Listenon
 
Lopac-S-8251
Lopac0_001080
Lysthenon
MolPort-002-964-486
NCGC00015971-01
NCGC00015971-03
NCGC00162336-01
Quelicin
Quelicin Preservative Free
SCK
ST50437287
STK177290
Scoline
Succicuran
Succinic acid, diester with choline
Succinic acid, diester with choline chloride
Succinocholine
Succinoylcholine
Succinyl choline
Succinylbischoline
Succinylcholine
Succinylcholine Chloride
Succinyldicholine
Sucostrin
Suxamethonium
Suxamethonium chloride
UNII-J2R869A8YF
ZINC01530820
succinylcholine
succinyldicholine
trimethyl-[2-[4-oxo-4-(2-trimethylazaniumylethoxy)butanoyl]oxyethyl]azanium diio
trimethyl-[2-[4-oxo-4-[2-(trimethylazaniumyl)ethoxy]butanoyl]oxyethyl]azanium
21
Vitamin Capproved, nutraceuticalPhase 4, Phase 2, Phase 153150-81-75785, 54670067
Synonyms:
(+)-Sodium L-ascorbate
(+)-ascorbate
(+)-ascorbic acid
(2R)-2-[(1S)-1,2-Dihydroxyethyl]-4,5-dihydroxy-furan-3-one
(2R)-2-[(1S)-1,2-dihydroxyethyl]-4,5-dihydroxyfuran-3-one
(5R)-5-[(1S)-1,2-dihydroxyethyl]-3,4-dihydroxyfuran-2(5H)-one
129940-97-2
134-03-2 (monosodium salt)
14536-17-5
154170-90-8
2-(1,2-Dihydroxyethyl)-4,5-dihydroxyfuran-3-one
255564_SIAL
259133-78-3
3-Keto-L-gulofuranolactone
3-Oxo-L-gulofuranolactone
3-Oxo-L-gulofuranolactone (enol form)
30208-61-8
33034_RIEDEL
33034_SIAL
47863_SUPELCO
47A605F0-4187-47A8-B0CE-F9E7DA1B0076
50-81-7
50976-75-5
56172-55-5
56533-05-2
57304-74-2
57606-40-3
623158-95-2
6730-29-6
882690-91-7
884381-69-5
885512-24-3
88845-26-5
89924-69-6
95209_FLUKA
95209_SIGMA
95210_FLUKA
95210_SIAL
95212_FLUKA
A0278_SIGMA
A0537
A2174_SIGMA
A2218_SIGMA
A2343_SIGMA
A4403_SIGMA
A4544_SIGMA
A5960_SIGMA
A7506_SIGMA
A92902_ALDRICH
A92902_SIAL
AB00376923
AB1002440
AC1L1L4T
AC1Q77S6
AR-1J3435
Acid Ascorbic
Acide ascorbique
Acide ascorbique [INN-French]
Acido ascorbico
Acido ascorbico [INN-Spanish]
Acidum ascorbicum
Acidum ascorbicum [INN-Latin]
Acidum ascorbinicum
Adenex
Allercorb
Ambap36431-82-0
Antiscorbic vitamin
Antiscorbutic factor
Antiscorbutic vitamin
Arco-cee
Ascoltin
Ascoltin (TN)
Ascor-B.I.D.
Ascorb
Ascorbajen
Ascorbate
Ascorbic Acid
Ascorbic Acid, Monosodium Salt
Ascorbic acid
Ascorbic acid (JP15/USP/INN)
Ascorbic acid [BAN:INN:JAN]
Ascorbic acid [INN:BAN:JAN]
Ascorbicab
Ascorbicap
Ascorbicap (TN)
Ascorbicin
Ascorbin
Ascorbinsaeure
Ascorbinsäure
Ascorbutina
Ascorbyl radical
Ascorin
Ascorteal
Ascorvit
BPBio1_000363
BSPBio_000329
C-Level
C-Long
C-Quin
C-Span
C-Vimin
C00072
C6H8O6
CCRIS 57
CE-VI-Sol
CHEBI:29073
CHEMBL196
CID5785
Cantan
Cantaxin
Caswell No. 061B
Catavin C
Ce lent
Ce-Mi-Lin
Ce-mi-lin
Ce-vi-sol
Cebicure
Cebid
Cebion
Cebione
Cecon
Cee-Caps TD
Cee-Vite
Cee-caps TD
Cee-vite
Cegiolan
Ceglion
Ceklin
Celaskon
Celin
Cell C
Cemagyl
Cemill
Cenetone
Cenolate
Cereon
Cergona
Cescorbat
Cetamid
Cetane
Cetane-Caps TC
Cetane-Caps TD
Cetane-caps TC
Cetane-caps TD
Cetebe
Cetemican
Cevalin
 
Cevatine
Cevex
Cevi-Bid
Cevi-bid
Cevimin
Cevital
Cevitamate
Cevitamic acid
Cevitamin
Cevitan
Cevitex
Cewin
Chewcee
Ciamin
Cipca
Citriscorb
Citrovit
Colascor
Concemin
Cortalex
D00018
DB00126
Davitamon C
Dora-C-500
Duoscorb
EINECS 200-066-2
FEMA No. 2109
Ferancee
Ferrous ascorbate
HSDB 818
HiCee
Hicee
Hybrin
IDO-C
Ido-C
Iron(II) ascorbate
Iron-ascorbic acid complexes
Juvamine
Kangbingfeng
Kyselina askorbova
Kyselina askorbova [Czech]
L(+)-Ascorbate
L(+)-Ascorbic acid
L-(+)-Ascorbate
L-(+)-Ascorbic Acid
L-(+)-Ascorbic acid
L-(+)-ascorbic acid
L-3-Ketothreohexuronic acid lactone
L-3-ketothreohexuronic acid
L-Ascorbate
L-Ascorbic Acid
L-Ascorbic acid
L-Ascorbic acid, free radical form
L-Lyxoascorbate
L-Lyxoascorbic acid
L-Threo-ascorbic acid
L-Threoascorbic acid
L-Xyloascorbate
L-Xyloascorbic acid
L-ascorbate
L-threo-Hex-2-enonic acid, gamma-lactone
L-threo-ascorbic acid
L-threo-hex-2-enono-1,4-lactone
LS-145
Laroscorbine
Lemascorb
Liqui-Cee
Liqui-cee
MLS002153776
Magnesium Ascorbicum
Magnorbin
Meri-C
Meri-c
MolPort-001-792-501
Monodehydroascorbic acid
NCGC00091517-01
NCGC00091517-02
NCGC00164357-01
NCI-C54808
NSC 33832
Natrascorb
Natrascorb injectable
Oral Vitamin C
Planavit C
Prestwick3_000325
Proscorbin
Redoxon
Ribena
Ronotec 100
Rontex 100
Roscorbic
Rovimix C
SMR001233160
Scorbacid
Scorbu C
Scorbu-C
Secorbate
Semidehydroascorbate
Sodascorbate
Sodium Ascorbate (Ascorbic Acid)
Stuartinic
Suncoat VC 40
Sunkist
Testascorbic
Tolfrinic
UNII-PQ6CK8PD0R
VASC
Vicelat
Vicin
Vicomin C
Viforcit
Viscorin
Viscorin 100M
Vitace
Vitacee
Vitacimin
Vitacin
Vitamin C
Vitamin- C
Vitamin-?C
Vitamisin
Vitascorbol
W210901_ALDRICH
Xitix
acide ascorbique
acidum ascorbicum
acidum ascorbinicum
antiscorbic vita min
ascor-b.i.d
ascorbate
ascorbic acid
bmse000182
cee-caps td
cevibid
component of Cortalex
component of E and C-Level
component of Endoglobin Forte
component of Ferancee
gamma-Lactone L-threo-Hex-2-enonate
gamma-Lactone L-threo-Hex-2-enonic acid
l-ascorbic acid
l-threo-hex-1-eofuranos-3-ulose
nchembio.174-comp5
nchembio.89-comp1
nchembio.92-comp2
nchembio821-comp9
roscorbi c
vitamin C
ácido ascórbico
22Antimetabolites, AntineoplasticPhase 4, Phase 3, Phase 2, Phase 1, Early Phase 17361
23Hormone AntagonistsPhase 4, Phase 3, Phase 2, Phase 113180
24HormonesPhase 4, Phase 3, Phase 2, Phase 114415
25Hormones, Hormone Substitutes, and Hormone AntagonistsPhase 4, Phase 3, Phase 2, Phase 113168
26Dermatologic AgentsPhase 4, Phase 3, Phase 2, Phase 15806
27AntimetabolitesPhase 4, Phase 3, Phase 2, Phase 1, Early Phase 112054
28Antifungal AgentsPhase 4, Phase 3, Phase 2, Phase 13696
29HematinicsPhase 4, Phase 2, Phase 3, Phase 11684
30VitaminsPhase 4, Phase 2, Phase 3, Phase 15282
31Peripheral Nervous System AgentsPhase 4, Phase 3, Phase 2, Phase 123689
32Antineoplastic Agents, AlkylatingPhase 4, Phase 3, Phase 2, Phase 1, Early Phase 14603
33MicronutrientsPhase 4, Phase 2, Phase 3, Phase 16001
34Trace ElementsPhase 4, Phase 2, Phase 3, Phase 16001
35Epoetin alfaPhase 4, Phase 2, Phase 3, Phase 1658113427-24-0
36Calcineurin InhibitorsPhase 4, Phase 3, Phase 2, Phase 11622
37Antibiotics, AntitubercularPhase 4, Phase 3, Phase 2, Phase 17180
38Immunosuppressive AgentsPhase 4, Phase 3, Phase 2, Phase 1, Early Phase 113086
39Anti-Bacterial AgentsPhase 4, Phase 3, Phase 2, Phase 1, Early Phase 111226
40Protective AgentsPhase 4, Phase 2, Phase 3, Phase 17443
41Antiviral AgentsPhase 4, Phase 3, Phase 2, Phase 1, Early Phase 19967
42Antirheumatic AgentsPhase 4, Phase 3, Phase 2, Phase 1, Early Phase 110956
43Liver ExtractsPhase 4, Phase 3, Phase 2, Phase 1, Early Phase 14067
44Alkylating AgentsPhase 4, Phase 3, Phase 2, Phase 1, Early Phase 14827
45Anti-Infective AgentsPhase 4, Phase 3, Phase 2, Phase 1, Early Phase 122062
46Antilymphocyte SerumPhase 4, Phase 3, Phase 2, Phase 1408
47Topoisomerase InhibitorsPhase 4, Phase 3, Phase 2, Phase 15069
48AntioxidantsPhase 4, Phase 3, Phase 2, Phase 13050
49EchinocandinsPhase 4, Phase 3, Phase 2124
50Steroid Synthesis InhibitorsPhase 4, Phase 3, Phase 2, Phase 11763

Interventional clinical trials:

(show top 50)    (show all 1789)
idNameStatusNCT IDPhase
1A Phase Ⅳ Study of Decitabine in Myelodysplastic SyndromeUnknown statusNCT02013102Phase 4
2Decitabine for Myelodysplastic Syndromes and Acute Myeloid Leukemia Before Allogeneic Hematopoietic Cell TransplantationUnknown statusNCT01806116Phase 4
3Antithymocyte Globulin and Cyclosporine in Treating Low Risk Patients With Myelodysplastic SyndromeCompletedNCT00488436Phase 4
4Study of Azacitidine in Adult Taiwanese Subjects With Higher-Risk Myelodysplastic Syndromes (MDS)CompletedNCT01201811Phase 4
5Evaluating the Efficacy of Deferasirox in Transfusion Dependent Chronic Anaemias (Myelodysplastic Syndrome, Beta-thalassaemia Patients) With Chronic Iron OverloadCompletedNCT00564941Phase 4
6A Study for Dacogen Treatment in Patients With Myelodysplastic SyndromeCompletedNCT01041846Phase 4
7An Observational Study for Dacogen Long-Term Treatment in Patients With Myelodysplastic SyndromeCompletedNCT01400633Phase 4
8Survey on QUality of Life In myeloDisplasia (SQUID)CompletedNCT00967564Phase 4
9SMD_FLAG-IDA_98: FLAG-IDA in Induction Treatment of High Risk Myelodysplastic Syndromes or Secondary Acute Myeloblastic LeukemiaCompletedNCT00487448Phase 4
10Evaluation the Effect of Exjade on Oxidative Stress in Low Risk Myelodysplastic Syndrome Patients With Iron Over LoadCompletedNCT00452660Phase 4
11Efficacy and Safety of Deferasirox in Patients With Myelodysplastic Syndrome and Transfusion-dependent Iron OverloadCompletedNCT00481143Phase 4
12This Study Will Evaluate Efficacy and Safety of Deferasirox in Patients With Myelodysplastic Syndromes (MDS), Thalassemia and Rare Anemia Types Having Transfusion-induced Iron Overload.CompletedNCT01250951Phase 4
13Magnetic Resonance Imaging (MRI) Assessments of the Heart and Liver Iron Load in Patients With Transfusion Induced Iron OverloadCompletedNCT00673608Phase 4
14Busulfan Safety/Efficacy as Conditioning Prior to Hematopoietic Cell Transplantation (HCT)CompletedNCT00361140Phase 4
15Bone Marrow Transplantation in Treating Patients With Hematologic CancerCompletedNCT00003398Phase 4
16Study Comparing Piperacillin-tazobactam Versus Piperacillin-tazobactam Plus Glycopeptide in Neutropenic PatientsCompletedNCT00195533Phase 4
17Analysis of Data Collected in the European Group for Blood and Marrow Transplantation (EBMT) Registry for Off-Label Transplant Use of PlerixaforCompletedNCT01362985Phase 4
18Eculizumab Pharmacokinetics/Pharmacodynamics Study in Pediatric/Adolescent PNH SubjectsCompletedNCT00867932Phase 4
19A Phase II Pilot Study to Assess the Presence of Molecular Factors Predictive for Hematologic Response in Myelodysplastic Syndrome Patients Receiving Deferasirox Therapy.RecruitingNCT02663752Phase 4
20A Study of Epoetin Beta Treatment in Anemic Participants With Myelodysplastic Syndrome (MDS)RecruitingNCT02145026Phase 4
21Pharmacokinetics of Posaconazole (Noxafil®) as Prophylaxis for Invasive Fungal InfectionsRecruitingNCT02805946Phase 4
22A Rollover Study to Provide Continued Treatment With EltrombopagRecruitingNCT01957176Phase 4
23Radium-223 Dichloride Long-term Follow-up ProgramRecruitingNCT02312960Phase 4
24Posaconazole Versus Micafungin for Prophylaxis Against Invasive Fungal Infections During Neutropenia in Patients Undergoing Chemotherapy for Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia or Myelodysplastic SyndromeActive, not recruitingNCT01200355Phase 4
25Plasmatic L-AScorbic Acid in MYelodyplastic Syndroms and ControlsNot yet recruitingNCT02809222Phase 4
26Busulfan and Cyclophosphamide Instead of Total Boby Irradiation (TBI) and Cyclophosphamide for Hematological Malignancies Hematocrit (HCT)Not yet recruitingNCT01339988Phase 4
27King's Invasive Aspergillosis Study IINot yet recruitingNCT02875743Phase 4
28A Randomized Phase IV Control Trial of Single High Dose Oral Vitamin D3 in Pediatric Patients Undergoing HSCTNot yet recruitingNCT03176849Phase 4
29Myelodysplastic Syndrome (MDS) Gastrointestinal (GI) Tolerability StudyTerminatedNCT01326845Phase 4
30To Demonstrate Superiority of Decitabine Over Azacitidine in Subjects With Intermediate- or High-risk MDS.TerminatedNCT01011283Phase 4
31Transfusion Effects in Myelodysplastic Patients: Limiting ExposureWithdrawnNCT00202371Phase 4
32The Effect of Combination Ultra Q10 and L-carnitine on the Course of Myelodysplastic SyndromeUnknown statusNCT02042482Phase 2, Phase 3
33Erythropoietin (EPO) and Granulocyte-Colony Stimulating Factor (G-CSF) for Low-Risk Myelodysplastic Syndromes (MDS)Unknown statusNCT00234143Phase 2, Phase 3
34Comparison Study of Standard Care Against Combination of Growth Factors Agents for Low-risk Myelodysplastic SyndromesUnknown statusNCT01196715Phase 3
35Combination Chemotherapy With or Without Peripheral Stem Cell Transplantation in Treating Patients With Myelodysplastic Syndrome or Acute Myelogenous LeukemiaUnknown statusNCT00002926Phase 3
36Low-Dose Decitabine Compared With Standard Supportive Care in Treating Older Patients With Myelodysplastic SyndromeUnknown statusNCT00043134Phase 3
37Combination Chemotherapy With or Without Idarubicin and Peripheral Stem Cell Transplantation in Treating Patients With Leukemia or Myelodysplastic SyndromeUnknown statusNCT00002989Phase 3
38Donor Stem Cell Transplant With or Without Chemotherapy in Treating Children With Primary Myelodysplastic SyndromeUnknown statusNCT00047268Phase 3
39Decitabine Augments for Post Allogeneic Stem Cell Transplantation in Patients With Acute Myeloid Leukemia and Myelodysplastic SyndromeUnknown statusNCT01809392Phase 2, Phase 3
40Efficacy Study of CHG Regimen vs Decitabine to Treat Higher-risk MDSUnknown statusNCT01417767Phase 2, Phase 3
41Combination Chemotherapy in Treating Older Patients With Acute Myeloid LeukemiaUnknown statusNCT00003602Phase 3
42Bone Marrow Angiogenesis in Acute Myeloid Leukemia - Evaluated by Dynamic Contrast Enhanced Magnetic Resonance (MR) ImageUnknown statusNCT00172562Phase 3
43Ketamine Hydrochloride and Best Pain Management in Treating Cancer Patients With Neuropathic PainUnknown statusNCT01316744Phase 3
44Thymoglobulin in Unrelated Hematopoietic Progenitor Cell TransplantationUnknown statusNCT01217723Phase 3
45Bowel Preparation and Prokinetics in Capsule EndoscopyUnknown statusNCT00275184Phase 3
46Treatment of Adults Aged Up to 60 Years With De Novo Acute Myeloblastic Leukaemia,Secondary AML, or RAEB-TUnknown statusNCT00209833Phase 2, Phase 3
47The Paroxysmal Nocturnal Hemoglobinuria Early Access Treatment ProtocolApproved for marketingNCT00438789Phase 3
48An Effectiveness and Safety Study of Decitabine in Patients With Myelodysplastic SyndromeCompletedNCT01751867Phase 3
49Antithymocyte Globulin and Cyclosporine in Treating Patients With Myelodysplastic SyndromeCompletedNCT00004208Phase 3
50An Efficacy Study for Epoetin Alfa in Anemic Patients With Myelodysplastic SyndromesCompletedNCT01381809Phase 3

Search NIH Clinical Center for Myelodysplastic Syndrome

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Myelodysplastic Syndrome cell therapies at LifeMap Discovery.

Genetic Tests for Myelodysplastic Syndrome

About this section

Genetic tests related to Myelodysplastic Syndrome:

id Genetic test Affiliating Genes
1 Myelodysplastic Syndrome27
2 Myelodysplastic Syndrome, Somatic24 ASXL1, SF3B1, TET2

Anatomical Context for Myelodysplastic Syndrome

About this section

MalaCards organs/tissues related to Myelodysplastic Syndrome:

36
Myeloid, Bone, Bone marrow, T cells, Testes, Skin, Neutrophil

LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Myelodysplastic Syndrome:
id TissueAnatomical CompartmentCell Relevance
1 PlacentaChorionic VillusChorionic Mesenchymal Stromal Cells Potential therapeutic candidate
2 Umbilical CordWharton's JellyMesenchymal Stem Cells Potential therapeutic candidate
3 BloodCord BloodMesenchymal Stem Cells Potential therapeutic candidate

Publications for Myelodysplastic Syndrome

About this section

Articles related to Myelodysplastic Syndrome:

(show top 50)    (show all 2184)
idTitleAuthorsYear
1
Long-term persistent donor-recipient mixed chimerism without disease recurrence after myeloablative single-unit cord blood transplantation in adult acute myeloid leukemia following myelodysplastic syndrome. (28509586)
2017
2
Allogeneic hematopoietic stem cell transplant in adult patients with myelodysplastic syndrome/myeloproliferative neoplasm (MDS/MPN) overlap syndromes. (27687869)
2017
3
Germline SAMD9 mutation in siblings with monosomy 7 and myelodysplastic syndrome. (28487541)
2017
4
Total coumarins of Hedyotis diffusa induces apoptosis of myelodysplastic syndrome SKM-1 cells by activation of caspases and inhibition of PI3K/Akt pathway proteins. (27988397)
2017
5
Correction: Rapidly Progressing Myelodysplastic Syndrome Initially Presenting as Acute Leukemia. (28465876)
2017
6
Relapsing Polychondritis with Myelodysplastic Syndrome: A Case Report. (28215949)
2017
7
Rapidly progressive hemorrhagic pneumonia caused by Stenotrophomonas maltophilia occurring early after bone marrow transplantation in a patient with myelodysplastic syndrome. (28484160)
2017
8
Dose-Reduced Versus Standard Conditioning Followed by Allogeneic Stem-Cell Transplantation for Patients With Myelodysplastic Syndrome: A Prospective Randomized Phase III Study of the EBMT (RICMAC Trial). (28463633)
2017
9
An Unlikely Rapid Transformation of Myelodysplastic Syndrome to Acute Leukemia: A Case Report. (28488979)
2017
10
Calreticulin mutations are exceedingly rare in patients with myelodysplastic syndromes with myelofibrosis. (27730343)
2017
11
Myelodysplastic Syndrome Developing Presacral Extramedullary Hematopoiesis with Atypical MRI Findings. (28502939)
2017
12
Reduced intensity conditioning of allogeneic hematopoietic stem cell transplantation for myelodysplastic syndrome and acute myeloid leukemia in patients older than 50A years of age: a systematic review and meta-analysis. (28470473)
2017
13
Validation of the revised International Prognostic Scoring System in patients with myelodysplastic syndrome in Japan: results from a prospective multicenter registry. (28497239)
2017
14
A randomized study comparing stem cell transplantation vs conventional therapy for low and intermediate risk myelodysplastic syndrome patients. (28494646)
2017
15
WT1 Expression in Patients with Myelodysplastic Syndromes: A Variety of Possibilities in Future Clinical Practice. (27871071)
2017
16
Wilms Tumor 1 (WT1) mRNA Expression Level at Diagnosis Is a Significant Prognostic Marker in Elderly Patients with Myelodysplastic Syndrome. (27866185)
2017
17
New polymorphisms of Xeroderma Pigmentosum DNA repair genes in myelodysplastic syndrome. (28472728)
2017
18
BCL2L10 positive cells in bone marrow are an independent prognostic factor of azacitidine outcome in myelodysplastic syndrome and acute myeloid leukemia. (28514758)
2017
19
Fatal Relapse of Myelodysplastic Syndrome in a Patient with HIV/Hepatitis C Coinfection Treated with Simeprevir/Sofosbuvir. (28088870)
2017
20
Presence of new mutations in the TP53 gene in patients with low-risk myelodysplastic syndrome: two case reports. (28527473)
2017
21
A case of GATA2-related myelodysplastic syndrome with unbalanced translocation der(1;7)(q10;p10). (28066994)
2017
22
Validation of the 2016 Revisions to the WHO Classification in Lower-Risk Myelodysplastic Syndrome. (28456995)
2017
23
Reduced Intensity for Myelodysplastic Syndrome: Worth the Gamble? (28463632)
2017
24
MicroRNAs and tRNA-derived fragments predict the transformation of myelodysplastic syndromes to acute myeloid leukemia. (28084850)
2017
25
CD34(+) megakaryocytes and megakaryocytic fragments in myelodysplastic syndrome. (28522465)
2017
26
Successful haploidentical BMT with post-transplant cyclophosphamide for refractory autoimmune pancytopenia after cord blood transplant in pediatric myelodysplastic syndrome. (28067878)
2017
27
Annotating Function to Differentially Expressed LincRNAs in Myelodysplastic Syndrome Using a Network-Based Method. (28472271)
2017
28
Iron overload promotes erythroid apoptosis through regulating HIF-1a/ROS signaling pathway in patients with myelodysplastic syndrome. (28460338)
2017
29
Generalised granuloma annulare associated with myelodysplastic syndrome. (27212203)
2016
30
Comment: In response to "Megaloblastic Anemia with Ring Sideroblasts is not Always Myelodysplastic Syndrome. (27956372)
2016
31
Prognostic pre-transplant factors in myelodysplastic syndromes primarily treated by high dose allogeneic hematopoietic stem cell transplantation: a retrospective study of the MDS subcommittee of the CMWP of the EBMT. (27650829)
2016
32
Genetic landscape of recurrent ASXL1, U2AF1, SF3B1, SRSF2, and EZH2 mutations in 304 Chinese patients with myelodysplastic syndromes. (26508027)
2016
33
High expression of the human equilibrative nucleoside transporter 1 gene predicts a good response to decitabine in patients with myelodysplastic syndrome. (26944860)
2016
34
Increased expression of HERG K(+) channels contributes to myelodysplastic syndrome progression and displays correlation with prognosis stratification. (27077769)
2016
35
Genomic loss of EZH2 leads to epigenetic modifications and overexpression of the HOX gene clusters in myelodysplastic syndrome. (26812882)
2016
36
Random-start controlled ovarian stimulation for emergency fertility preservation in a patient with myelodysplastic syndrome: a case report. (27191608)
2016
37
MHC Class I Chain-Related Gene A (MICA) Donor-Recipient Mismatches and MICA-129 Polymorphism in Unrelated Donor Hematopoietic Cell Transplantations Has No Impact on Outcomes in Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, or Myelodysplastic Syndrome: A Center for International Blood and Marrow Transplant Research Study. (27987385)
2016
38
Non-myeloablative conditioning for lower-risk myelodysplastic syndrome with bone marrow blasts less than 5A %-a feasibility study. (27106699)
2016
39
Copy number neutral loss of heterozygosity at 17p and homozygous mutations of TP53 are associated with complex chromosomal aberrations in patients newly diagnosed with myelodysplastic syndromes. (26851439)
2016
40
Hemochromatosis gene mutations may affect the survival of patients with myelodysplastic syndrome. (27077775)
2016
41
A Case of Sweet's Syndrome Secondary to Myelodysplastic Syndrome - Diagnostic and Treatment Challenges. (28461837)
2016
42
Use of darbepoetin alfa for myelodysplastic syndrome coincident with chronic kidney disease. (28509181)
2016
43
Work up for the clopidogrel hypersensitivity that led to recognising the undiagnosed myelodysplastic syndrome. (27103925)
2016
44
Myelodysplastic Syndrome Associated with Acquired Beta Thalassemia: "BTMDS". (27121565)
2016
45
The Simultaneous Elevation of Oxidative Stress Markers and Wilms' Tumor 1 Gene during the Progression of Myelodysplastic Syndrome. (27980269)
2016
46
Dyspoietic changes associated with hepatosplenic T-cell lymphoma are not a manifestation of a myelodysplastic syndrome: analysis of 25 patients. (26997444)
2016
47
IDH1 and IDH2 mutations in myelodysplastic syndromes and role in disease progression. (26228814)
2016
48
Results of a phase II study of thalidomide and azacitidine in patients with clinically advanced myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML) and low blast count acute myeloid leukemia (AML). (27268068)
2016
49
Spectrum of complex chromosomal aberrations in a myelodysplastic syndrome and a brief review. (28054536)
2016
50
A phase II study of vascular endothelial growth factor trap (Aflibercept, NSC 724770) in patients with myelodysplastic syndrome: a California Cancer Consortium Study. (27650362)
2016

Variations for Myelodysplastic Syndrome

About this section

UniProtKB/Swiss-Prot genetic disease variations for Myelodysplastic Syndrome:

70
id Symbol AA change Variation ID SNP ID
1GATA2p.Thr354MetVAR_066406rs387906631
2SETBP1p.Asp868AsnVAR_063807rs267607042
3SETBP1p.Gly870SerVAR_063809rs267607040
4SETBP1p.Ser869AsnVAR_069852
5SETBP1p.Thr873ArgVAR_069857

Clinvar genetic disease variations for Myelodysplastic Syndrome:

5 (show all 37)
id Gene Variation Type Significance SNP ID Assembly Location
1TP53NM_ 000546.5(TP53): c.742C> T (p.Arg248Trp)SNVPathogenic/ Likely pathogenicrs121912651GRCh37Chr 17, 7577539: 7577539
2TP53NM_ 000546.5(TP53): c.743G> A (p.Arg248Gln)SNVPathogenic/ Likely pathogenicrs11540652GRCh37Chr 17, 7577538: 7577538
3HRASNM_ 005343.3(HRAS): c.34G> A (p.Gly12Ser)SNVPathogenic/ Likely pathogenicrs104894229GRCh37Chr 11, 534289: 534289
4HRASNM_ 005343.3(HRAS): c.35G> C (p.Gly12Ala)SNVPathogenic/ Likely pathogenicrs104894230GRCh37Chr 11, 534288: 534288
5HRASNM_ 005343.3(HRAS): c.34G> T (p.Gly12Cys)SNVPathogenic/ Likely pathogenicrs104894229GRCh37Chr 11, 534289: 534289
6NRASNM_ 002524.4(NRAS): c.37G> C (p.Gly13Arg)SNVPathogenic/ Likely pathogenicrs121434595GRCh37Chr 1, 115258745: 115258745
7NRASNM_ 002524.4(NRAS): c.38G> A (p.Gly13Asp)SNVPathogenic/ Likely pathogenicrs121434596GRCh37Chr 1, 115258744: 115258744
8IDH2NM_ 002168.3(IDH2): c.419G> A (p.Arg140Gln)SNVPathogenic/ Likely pathogenicrs121913502GRCh37Chr 15, 90631934: 90631934
9IDH1NM_ 001282386.1(IDH1): c.395G> A (p.Arg132His)SNVPathogenic/ Likely pathogenicrs121913500GRCh38Chr 2, 208248388: 208248388
10NRASNM_ 002524.4(NRAS): c.34G> A (p.Gly12Ser)SNVPathogenic/ Likely pathogenicrs121913250GRCh37Chr 1, 115258748: 115258748
11NRASNM_ 002524.4(NRAS): c.35G> C (p.Gly12Ala)SNVPathogenic/ Likely pathogenicrs121913237GRCh38Chr 1, 114716126: 114716126
12SF3B1NM_ 012433.3(SF3B1): c.1998G> T (p.Lys666Asn)SNVPathogenic/ Likely pathogenicrs377023736GRCh37Chr 2, 198267359: 198267359
13TP53NM_ 000546.5(TP53): c.743G> T (p.Arg248Leu)SNVLikely pathogenicrs11540652GRCh37Chr 17, 7577538: 7577538
14TP53NM_ 000546.5(TP53): c.743G> C (p.Arg248Pro)SNVLikely pathogenicrs11540652GRCh37Chr 17, 7577538: 7577538
15GATA2NM_ 001145661.1(GATA2): c.1061C> T (p.Thr354Met)SNVPathogenic/ Likely pathogenic, risk factorrs387906631GRCh37Chr 3, 128200744: 128200744
16GATA2GATA2, 3-BP DEL, 1063ACAdeletionrisk factor
17NRASNM_ 002524.4(NRAS): c.38G> T (p.Gly13Val)SNVPathogenic/ Likely pathogenicrs121434596GRCh37Chr 1, 115258744: 115258744
18DNMT3ANM_ 175629.2(DNMT3A): c.2645G> C (p.Arg882Pro)SNVPathogenic/ Likely pathogenicrs147001633GRCh37Chr 2, 25457242: 25457242
19DNMT3ANM_ 175629.2(DNMT3A): c.2645G> A (p.Arg882His)SNVPathogenic/ Likely pathogenicrs147001633GRCh37Chr 2, 25457242: 25457242
20DNMT3ANM_ 175629.2(DNMT3A): c.2644C> T (p.Arg882Cys)SNVPathogenic/ Likely pathogenicrs377577594GRCh37Chr 2, 25457243: 25457243
21IDH1NM_ 005896.3(IDH1): c.395G> T (p.Arg132Leu)SNVPathogenic/ Likely pathogenicrs121913500GRCh37Chr 2, 209113112: 209113112
22IDH1NM_ 001282387.1(IDH1): c.394C> T (p.Arg132Cys)SNVPathogenic/ Likely pathogenicrs121913499GRCh37Chr 2, 209113113: 209113113
23IDH1NM_ 001282387.1(IDH1): c.394C> G (p.Arg132Gly)SNVPathogenic/ Likely pathogenicrs121913499GRCh37Chr 2, 209113113: 209113113
24IDH1NM_ 001282387.1(IDH1): c.394C> A (p.Arg132Ser)SNVPathogenic/ Likely pathogenicrs121913499GRCh37Chr 2, 209113113: 209113113
25IDH2NM_ 001289910.1(IDH2): c.359G> A (p.Arg120Lys)SNVPathogenic/ Likely pathogenicrs121913503GRCh37Chr 15, 90631838: 90631838
26IDH2NM_ 002168.3(IDH2): c.419G> T (p.Arg140Leu)SNVPathogenic/ Likely pathogenicrs121913502GRCh37Chr 15, 90631934: 90631934
27IDH2NM_ 002168.3(IDH2): c.418C> T (p.Arg140Trp)SNVPathogenic/ Likely pathogenicrs267606870GRCh37Chr 15, 90631935: 90631935
28U2AF1NM_ 001025203.1(U2AF1): c.470A> C (p.Gln157Pro)SNVLikely pathogenicrs371246226GRCh37Chr 21, 44514777: 44514777
29U2AF1NM_ 006758.2(U2AF1): c.101C> T (p.Ser34Phe)SNVLikely pathogenicrs371769427GRCh37Chr 21, 44524456: 44524456
30U2AF1NM_ 001025203.1(U2AF1): c.101C> A (p.Ser34Tyr)SNVLikely pathogenicrs371769427GRCh37Chr 21, 44524456: 44524456
31SF3B2NM_ 006842.2(SF3B2): c.2099A> G (p.Glu700Gly)SNVLikely pathogenicrs1057519960GRCh37Chr 11, 65830884: 65830884
32TP53NM_ 000546.5(TP53): c.742C> G (p.Arg248Gly)SNVLikely pathogenicrs121912651GRCh37Chr 17, 7577539: 7577539
33NRASNM_ 002524.4(NRAS): c.35G> A (p.Gly12Asp)SNVPathogenic/ Likely pathogenicrs121913237GRCh37Chr 1, 115258747: 115258747
34NRASNM_ 002524.4(NRAS): c.34G> T (p.Gly12Cys)SNVPathogenic/ Likely pathogenicrs121913250GRCh37Chr 1, 115258748: 115258748
35NRASNM_ 002524.4(NRAS): c.34G> C (p.Gly12Arg)SNVPathogenic/ Likely pathogenicrs121913250GRCh37Chr 1, 115258748: 115258748
36NRASNM_ 002524.4(NRAS): c.35G> T (p.Gly12Val)SNVPathogenic/ Likely pathogenicrs121913237GRCh37Chr 1, 115258747: 115258747
37MT-TL1m.3242G> ASNVPathogenicrs193303018GRCh37Chr MT, 3242: 3242

Copy number variations for Myelodysplastic Syndrome from CNVD:

6 (show top 50)    (show all 82)
id CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
11842311455409229473750DeletionMyelodysplastic syndrome
23324014380347543820135MutationMPLMyelodysplastic syndrome
34083310133929972135293404DuplicationMyelodysplastic syndrome
444880106450000070600000LossMyelodysplastic syndrome
55072711119076986119178859MutationCBLMyelodysplastic syndrome
65120511123900000135006516GainMyelodysplastic syndrome
75149911127052052133951370DuplicationMyelodysplastic syndrome
8524511117331912138300DuplicationMyelodysplastic syndrome
962482121088975625048970DeletionMyelodysplastic syndrome
10659831223940132382344DeletionMyelodysplastic syndrome
117280112868994410025942DeletionMyelodysplastic syndrome
1297766161310925613949702DeletionMyelodysplastic syndrome
131083961720280918798804DeletionMyelodysplastic syndrome
141083971720280922129948DeletionMyelodysplastic syndrome
15109400172580000031800000GainMyelodysplastic syndrome
16110294173180000038100000GainMyelodysplastic syndrome
17116723176968909978513583DuplicationMyelodysplastic syndrome
18116794176998740778623230DeletionMyelodysplastic syndrome
191181161775717207590868MutationP53Myelodysplastic syndrome
20121808184717427549624685DeletionMyelodysplastic syndrome
2112411619159128983DeletionMyelodysplastic syndrome
22128856194340000045200000DeletionMyelodysplastic syndrome
23131185195360000059128983AmplificationMyelodysplastic syndrome
241404062197400000204900000LossMyelodysplastic syndrome
25152708203247392033605249DeletionMyelodysplastic syndrome
26153104203440000049800000DeletionMyelodysplastic syndrome
27153115203450777656709287DeletionMyelodysplastic syndrome
28153160203485371751702925DeletionMyelodysplastic syndrome
29158211213050000046944323MicrodeletionRUNX1Myelodysplastic syndrome
30160489221543813331661481TriplicationMyelodysplastic syndrome
311684873130292954199251329DuplicationMyelodysplastic syndrome
321804704106067032106200960MutationTET2Myelodysplastic syndrome
331813664120601325121421102DeletionMAD2L1Myelodysplastic syndrome
341813674120601325121421102DeletionPDE5AMyelodysplastic syndrome
351813684120601325121421102DeletionSAR1P3Myelodysplastic syndrome
3618821846057719961810493DeletionMyelodysplastic syndrome
37188320462191591126940390DeletionMyelodysplastic syndrome
3818850646557879966861924DeletionEPHA5Myelodysplastic syndrome
3918990948019599082530576DeletionANTXR2Myelodysplastic syndrome
4018991048019599082530576DeletionARD1BMyelodysplastic syndrome
4118991148019599082530576DeletionBMP3Myelodysplastic syndrome
4218991248019599082530576DeletionC4orf22Myelodysplastic syndrome
4318991348019599082530576DeletionFGF5Myelodysplastic syndrome
4418991448019599082530576DeletionGK2Myelodysplastic syndrome
4518991548019599082530576DeletionPRDM8Myelodysplastic syndrome
4618991648019599082530576DeletionPRKG2Myelodysplastic syndrome
471918545102760027157708888DeletionMyelodysplastic syndrome
481931545125503105161513040DeletionMyelodysplastic syndrome
49200025548400000180915260DeletionGLRA1Myelodysplastic syndrome
50200026548400000180915260DeletionSH3TC2Myelodysplastic syndrome

Expression for genes affiliated with Myelodysplastic Syndrome

About this section
Search GEO for disease gene expression data for Myelodysplastic Syndrome.

Pathways for genes affiliated with Myelodysplastic Syndrome

About this section

GO Terms for genes affiliated with Myelodysplastic Syndrome

About this section

Biological processes related to Myelodysplastic Syndrome according to GeneCards Suite gene sharing:

(show all 11)
idNameGO IDScoreTop Affiliating Genes
1embryonic placenta developmentGO:000189211.1CSF2, GATA2
2dendritic cell differentiationGO:009702811.1CSF2, FLT3
3myeloid progenitor cell differentiationGO:000231811.1FLT3, MLF1, TET2
4positive regulation of DNA replicationGO:004574011.0CSF2, EPO, IL3
5hemopoiesisGO:003009711.0ASXL1, FLT3, GATA2, RUNX1, TET2
6positive regulation of tyrosine phosphorylation of Stat5 proteinGO:004252310.9CSF2, EPO, IL3
7positive regulation of cell proliferationGO:000828410.9CSF2, EPO, FLT3, IL3, NPM1
8positive regulation of tyrosine phosphorylation of STAT proteinGO:004253110.9CSF2, EPO, FLT3, IL3
9positive regulation of transcription from RNA polymerase II promoterGO:004594410.8ASXL1, GATA2, IRF1, NPM1, RUNX1, TET2
10positive regulation of transcription, DNA-templatedGO:004589310.8EPO, IRF1, NPM1, PRDM16, RUNX1, WT1
11transcription from RNA polymerase II promoterGO:000636610.2GATA2, IRF1, NPM1, RUNX1, WT1

Molecular functions related to Myelodysplastic Syndrome according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1C2H2 zinc finger domain bindingGO:007074211.1GATA2, WT1
2regulatory region DNA bindingGO:000097510.4IRF1, RUNX1
3DNA bindingGO:000367710.3ASXL1, GATA2, IRF1, MLF1, PRDM16, RUNX1

Sources for Myelodysplastic Syndrome

About this section
2CDC
6CNVD
10DGIdb
15ExPASy
16FDA
17FMA
27GTR
28HGMD
29HMDB
30ICD10
31ICD10 via Orphanet
32ICD9CM
33IUPHAR
34KEGG
37MedGen
39MeSH
40MESH via Orphanet
41MGI
44NCI
45NCIt
46NDF-RT
49NINDS
50Novoseek
52OMIM
53OMIM via Orphanet
57PubMed
58QIAGEN
63SNOMED-CT via Orphanet
67Tumor Gene Family of Databases
68UMLS
69UMLS via Orphanet